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 ABSTRACT 
 
Myocardial Infarction (MI) is one of the major cardiovascular diseases 
worldwide. It is caused by rupture of atherosclerotic plaque in coronary vessels. Genetic 
and environmental factors play a key role in the development of MI. The major objective 
of current study was to evaluate the association of genetic variants with lipid metabolism 
and predisposition risk factors along with environmental factors in MI patients of 
Pakistani population. The study was designed in two phases; the first phase included 
demographic characteristics and economic burden of MI while the association of genetics 
with MI was investigated in the second phase. A total of 515 patients of MI were 
recruited to identify the economic burden, life style, family history and risk factors 
(hypertension, diabetes, smoking and hyperlipidemia) with MI. In second phase 384 
Pakistani individuals were included for genetic analysis. A total of nine candidate genes 
with 22 SNPs were selected and genotyped by sequencing as well as one label extension 
method. The MI was significantly higher (P < 0.05) among males as compared to females 
in both urban and rural MI patients. The 43.11% patients were overweight (BMI ˃ 25). 
The urban MI patients were significantly more overweight as compared to rural patients 
(P < 0.05). The 72.04% patients were found with previous family history of heart attack. 
Smoking (60.9%) and sedentary life style (70%) were more common in MI patients. 
Sedentary life style was predominant in Urban MI patients as compared to rural MI 
patients. The average annual cost per patient was found 9524.53 PKRs (96.96 USD). In 
genetic analysis 15 SNPs (out of 22) from 9 candidate genes were significantly (P < 0.05) 
associated with elevated risk of MI. Overall current study was the first to identify three 
novel SNPs rs10757278, rs10811656 and rs10757283 on chromosome 9p21.3 
(CDKN2A/B gene) using 11 genetic markers, against MI in Pakistani population. The 
genetic variants rs10811656 risk allele T and rs10757278 risk allele G, rs10757283 risk 
allele T residing at chromosome 9p21.3 were found to be significantly associated with 
higher risk of MI [OR = 1.67 (1.22, 2.29), 1.37 (1.09, 1.72) and 1.47 (1.08, 2.01) 
respectively]. Two lipid metabolism related SNPs: rs662799 and rs3135506 of APOA5 
were associated with risk of higher triglyceride levels (266 mg/dl genotype GG and 244 
mg/dl genotype CC respectively) irrespective of age, gender, obesity, diabetes, 
hypertension and smoking. Four SNPs (rs2383206, rs2383207, rs10811656 and 
rs10757278) of CDKN2A/B (chromosome 9p21.3) were found in strong linkage 
disequilibrium [LD (D/ = 0.99)] and their minor allele frequencies were significantly 
more prevalent in patients than controls (P = 0.02, 0.0002, 0.0012, 0.005 respectively). 
The four SNPs from 9p21.3 showed one risk haplotype (G-A-T-G; P = 0.001) and two 
protective haplotypes (A-G-C-A and G-G-C-A; P = 0.006, 0.001 respectively) involved 
in progression of MI. In addition the SNPs rs3135506, rs1558861, rs662799 and 
rs10750097 residing in APOA5 gene were depicted strong linkage disequilibrium (D/ = 
0.99). Present study identified C-T-G-A and G-C-A-G haplotypes as risk haplotypes 
significantly (P = 0.0001) associated with MI. Higher BMI, smoking, hypertension, 
hyperlipidemia and diabetes were identified as strong predictor of MI in North Punjab 
Pakistan. Current study confirms correlation between lipid metabolism related SNPs and 
variants of 9p21.3 locus with MI as well as supporting the role of APOA5 in raising the 
triglyceride levels. Preventive measures are needed to start at early age and continue 
throughout the life course. However further studies are needed for delineating the role of 
these SNPs in MI development. 
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 CHAPTER 1 
 INTRODUCTION 
1.1 Myocardial infarction  
 Myocardial Infarction (MI) is a predominant and inevitable consequence of 
coronary heart disease (CHD) (Thygesen et al., 2007). MI commonly known as heart 
attack occurs when thrombosis is precipitated by rupture of atherosclerotic plaque, it 
leads to hypoxia and subsequential necrosis of the myocardium (Alpert et al., 2000).  
 The prevalence of CHD in USA during the year 2010 was 19.8% among age 
group of ≥ 65 years as compared to age range of 45 to 64 years (7.1%). When data was 
compared with different ethnic groups, it was further noticed burden of CHD in year 
2010 was higher among American Indians (11.6%) as compared to whites (5.8%) and 
Hispanics (6.1%) (Fang et al., 2011). 
 In 2005, globally total number of deaths by cardiac disease and stroke had been 
increased to 17.5 million comparing from14.4 million in 1990 (Go et al., 2013). Among 
these, 7.6 million deaths occurred only due to CHD (Dinc et al., 2013). CHD is the cause 
of more than 17.1 million deaths per year throughout the world (Chaudhry et al., 2012) 
and it will be most serious leading cause of death worldwide by 2020 (Murray and Lopez, 
1997). There were 39% deaths in low and middle income countries under the age of 70 
years due to CHD (Gaziano et al., 2010).  
Asian population is more susceptible to MI (Kearney et al., 2005; Joshi et al., 
2007). South Asia (India, Pakistan, Bangladesh, Nepal, and Sri Lanka) consists of more 
than quarter of developing world and was strongly affected by the increasing economic 
burden of CHD (Mc Keigue et al., 1989). It had been depicted that South Asians suffer 
from first heart attack at the age of 53 years, which is six years earlier than European 
countries (Gaziano et al., 2010). MI was 50% higher in South Asians, which bear greatest 
burden of coronary risk as compared to white people in the UK (Gholapa et al., 2011).  
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 In North India, the prevalence of CHD had been reported 11% in 2001 (Mohan et 
al., 2001). Pakistan is a developing country with the population of 187 million, it 
accounts for alarming cardiac disease burden, estimated that 5.0937 million people were 
affected by cardiovascular disease in year 2006 (Yousaf, 2012). Moreover, the Pakistan 
accounts for 35% to 40% of cardiac disease burden (Wasif, 2011). One out of five 
individuals suffers with CHD in urban areas of Pakistan (Jafar et al., 2005). As stated by 
National Health Survey of Pakistan, mortality due to CHD is increasing day by day 
(Memon and Samad, 1999).  
1.2 Types of MI 
The experts of European Society of Cardiology (ESC), the American Heart 
Association (AHA), the American College of Cardiology Foundation (ACCF) and the 
World Heart Federation (WHF) proposed the third new universal definition of MI as the 
elevation of cardiac biomarkers in blood with any one biomarker greater than 99th 
percentile as Upper Reference Limit (URL). In addition presence of one of the following 
symptoms; Ischemia, Electrocardiograph (ECG) changes or thrombus diagnosed by 
angiography (Daubert and Jeremias, 2010). According to new definition MI is divided 
into following five types (Thygesen et al., 2007). 
• ST Segment Elevation Myocardial Infarction—STEMI—Type I 
• Non-ST Segment Elevation Myocardial Infarction—NSTEMI—Type I 
• Type II 
• Type III 
• Type IV and V 
1.2.1 ST Segment Elevation Myocardial Infarction (STEMI) 
 The ST Segment Elevation Myocardial Infarction (STEMI) is a type of heart 
attack with damage over a large area of cardiac muscles (myocardium). In this type attack 
full thickness damage to myocardium take place. The ST-segment is a small portion of 
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ECG. It is characterized by the ECG changes in which elevation of ST segment shows 
complete thickness injury of myocardium (Van de Werf et al., 2008). Normal ECG is 
shown in Figure 1.1 (http://research.vet.upenn.edu). 
 
 
 
   
Figure 1.1: The waves of a single normal ECG pattern 
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1.2.2 Non- ST Segment Elevation Myocardial Infarction (NSTEMI) 
Non ST Segment Elevation Myocardial Infarction (NSTEMI) is not acompained 
by ST elevation and usually is not full-thickness infarction (Figure 1.2). The NSTEMI is 
less severe in comparison with STEMI type of heart attack. The NSTEMI does not 
changes the pattern of ECG but it is diagnosed by the presence of raised myocardial 
biomarkers in the blood (Troponin, creatin kinase and myoglobin). Troponin found in 
cardiac muscle fibers and its concentration ≥ 0.01 ng/mL in the blood stream indicating 
damage to heart muscles (Van de Werf et al., 2008). Differnce of STEMI and NSTEMI is 
explained in Figure 1.3.  
   
 
     
 
 
 
Figure 1.2: Partial damage to heart muscles in NSTEMI type of heart attack 
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Figure 1.3: Difference between STEMI and NSTEMI 
 
1.2.3 MI type 2 (Secondary to ischemia)  
It is secondary to ischemia caused by imbalance between supply and demand of 
oxygen. MI type 2 is caused by hypotension, anemia, coronary embolism, spasm of 
coronary artery and dysfunction of coronary endothelium.  
1.2.4 MI type 3 (Sudden infarction) 
Type 3 is a sudden infarction by fresh thrombus appearance in coronary artery 
before emergence of biomarkers in blood (Figure 1.4) 
 
.  
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                                                                                                     (a)                 
 
                                    
                      (b)                                                                                   (c) 
Figure 1.4: Differentiation between myocardial infarction according to the condition of the 
coronary arteries. (a) type 1 and 2 (b) type 3 (c)  type 4 and 5 (Thygesen et al., 
2007). 
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1.2.5 MI type 4 and type 5 (Stent thrombosis) 
 Infarction related to stent thrombosis or coronary bypass surgery . 
1.3 Pathophysiology 
 CHD is caused by atherosclerosis (the thickening and hardening of the inside 
walls of arteries). In atherosclerosis, plaque deposits develop in the arteries. Plaque is 
made up of fat, calcium, cholesterol and other substances from the blood (Thygesen et 
al., 2007). When a blood clot develops at the site of plaque in coronary artery then 
suddenly cuts off most of or all blood supply to that part of the heart muscles. If cells of 
myocardium do not receive enough oxygen they begin to die. This can cause the 
permanent damage to heart muscles. The process of plaque formation starts up in 
childhood, leads to young adults and appears with clinical symptoms in the middle age. It 
was demonstrated that endothelium injury can start the process of atherogenosis (Libby, 
2001) (Figure 1.5). 
 
 
Figure 1.5: Narrowing of a normal coronary artery (Atherosclerosis) (www.webmd.com) 
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1.4 Symptoms  
 The World Health Organization (WHO) had defined MI, as presence of two or 
three following symptoms; chest pain/discomfort of 30 min duration, imbalance in 
cardiac enzymes such as troponin I, creatine kinase, lactate dehydrogenase isozymes 
specific for the heart, typical electrocardiogram pattern and shortness of breath (Capewell 
et al., 2001). 
1.5 Risk factors  
 Genetic and environmental factors have been studied as being responsible for 
high risk of MI (Wang et al., 2008; Topol et al., 2006). Kannel. (2000) in his study has 
depicted six primary risk factors: age, obesity, hypertension, smoking, diabetes mellitus 
and hypercholesterolemia as major factors for the onset of CHD. Nuri et al. (2006) has 
demonstrated high prevalence of MI risk factors in Pakistan with more than 30% of the 
population affected by this disease over 45 years of age. Etiology of the CHD is not 
known, however the risk factors have strong statistical correlation with the onset of 
cardiac disease and its modification may lead to reduction in this disease (Goldstein et 
al., 2006).  
1.5.1 Age/Gender 
 The high prevalence of cardiac disease at the age of 45 years in men and 55 years 
in women was reported in Pakistan (Ahmad and Shafiq, 2003; Jafar et al., 2005). The 
male: female ratio of patients with coronary heart disease demonstrated as 3:1 along with 
gender age gap of 5 years (Jafar et al., 2005). These gender differences in the onset of MI 
become narrow with increasing age. Risk of MI increased in postmenopausal women and 
those who used oral contraceptive pills (Dunn et al., 2001).  
1.5.2 BMI/ Obesity 
 Obesity is defined as the total body fat contents of more than 20% in average 
young males and over 30% in females. Body Mass Index (BMI) more than 25 kg/m2 is 
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considered as overweight however, over 30 kg/m2 is considered as obese (Edelstein and 
Sharlin, 2008). High BMI (≥ 30 kg/m2) has been independently associated with risk of 
MI at early age (Gupta et al., 2003). More than 2.5 billion deaths are related with 
overweight worldwide (Brundtland, 2002). Asians have 3% to 5% higher body fat 
contents than whites at any given BMI (Prasad et al., 2011). Fat contents cause glucose 
intolerance and increased diabetes in South Asian countries (Gupta et al., 2006). The 
prevalence of obesity in rural areas of Peshawar Pakistan was much higher among 
females as compared to males (Hassan et al., 2005; Basit and Shera, 2008).  
1.5.3 Hypertension  
 High blood pressure (hypertension) is one of the most important preventable 
cause of number of diseases worldwide (Lloyd-Sherlock et al., 2014). It has strong 
relationship with heart disease. In Pakistan, the magnitude of hypertension is very high 
(Nishtar, 2002; Dodani et al., 2004; Yusuf et al., 2004). It was reported that number of 
hypertensive patients will expand to 60% by 2025 worldwide (Kearney et al., 2005).  
1.5.4 Diabetes  
 MI is the leading cause of death in diabetic patients and approximately 25 percent 
of heart attack survivors have diabetes (Fuuler et al., 2001). It is a more potent risk factor 
in women than men since diabetic women have twice the risk of a second heart attack 
compared to diabetic men (Gale and  Gillespie, 2001). South Asians have higher risk of 
type 2 diabetes (Nishtar, 2002), insulin resistance and bad fat distribution relative to other 
popultaions (Mc Keigue et al., 1989). It has been reported insulin resistance raised the 
risk of heart disease through inflammatory and lipid mediated mechanisms (Nishtar, 
2002). Pakistan ranks at number six in terms of diabetic people worldwide (Wasay and 
Jabbar, 2009). Risk of MI increased in diabetic patients because impaired glucose level 
take part in progression of atherosclerosis and badly affect the cholesterol levels (Cade, 
2008). 
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1.5.5 Cholesterol 
 Cholesterol is a steroid, used in the formation of cell walls, building of bile and 
hormones. A certain amount of cholesterol is necessary for good health but very high 
level in the blood is found to be associated with cardiac disease. Cholesterol enters the 
body from digestive system attached to the chylomicrons (lipoprotein particles) (Danik et 
al., 2008).  
1.5.5.1 The cholesterol carriers  
 Cholesterol does not dissolve in the blood, it is conveyed by some protein 
packages, which facilitate its solubility. These cholesterol transporters are lipoproteins, 
known as Very Low Density Lipoproteins (VLDL), Low Density Lipoproteins 
Cholesterol (LDL-C), High Density Lipoproteins Cholesterol (HDL-C) and chylomicrons 
(Alberts et al., 2002). 
VLDL is converted into LDL-C which is the bad cholesterol (Alberts et al., 
2002). LDL-C is potent transporters of cholesterol from liver to blood. It accumulates fats 
into blood. High plasma LDL-C level (≥ 160 mg/dl) leading to the formation of 
atherosclerotic plaque (Miller et al., 2011). On the other hand HDL-C (good cholesterol) 
has opposite function and involved in transport of blood cholesterol to liver where it can 
be degraded and lower the blood cholesterol levels. High HDL-C provides the great 
protection from CHD. Triglycerides are blood fats, higher triglycerides (≥ 200 mg/dl) are 
also important risk factor for progression of MI (Danik et al., 2008). It has been estimated 
that high triglyceride concentration involved in increasing the blood viscosity, resulting 
in the slow blood flow. Viscous blood is more difficult to flow, so very minor amount of 
oxygen is delivered to body tissues and heart.  
1.5.5.2 Hyperlipidemia 
 Hyperlipidemia stands as the third most important risk factor of CHD (Khan et 
al., 2005). It can cause blockage of coronary arteries and increase the risk of MI. 
INTERHEART study reported that abnormal lipid levels in blood are strongly associated 
with MI among South Asians (Chow et al., 2011). About 56% of heart diseases are 
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attributed to total serum cholesterol levels > 5.2 mmol/l or 200 mg/dl (Yusuf et al., 
2004). Hyperlipidemia accounts for 4.4 million deaths annually, which are 7.9% of the 
total global deaths and 2.8% of the total disease, burden worldwide (Shahid et al., 2009). 
Increased levels of LDL-C and Low plasma HDL-C are associated with higher incidence 
of both atherosclerosis and MI (Vergeer et al., 2010). 
1.5.6 Smoking 
 Smoking constitutes major factor in development of CHD. Even non-smokers, 
that inhaled smoke by any mean, also greatly increases MI risk (Whincup et al., 2004). 
Cigarette smoke contains more than 4,000 chemicals, which has pathophysiological 
effect on heart. Smoking promotes plaque formation and participates in acceleration of 
atherosclerosis (Ambrose and Barua, 2004). Many hematological, metabolical and 
physiological changes associated with smoking. Due to smoking, heart demands more 
oxygen but the capacity of its supply to heart reduces. It results in increased oxidative 
stress which indicates a potent mechanism for initiating cardiovascular dysfunction. 
(Goldstein and Niaura, 2000). Shahid et al. (2009) reported cessation of smoking can 
reduce the risk of heart disease by 65%. 
1.5.7 Life style 
 Pakistani children are acquiring unhealthy life style. Physical inactivity is 
constantly increasing among them (Khuwaja et al., 2003). Trends from physical activities 
i.e. active games and recreational sports have been changed to sedentary entertainment 
including extensive use of computer, television and video games. As a consequence 
Pakistani people develop CHD in their early age of 40 years (Gaziano et al., 2010). There 
is also an increasing trend of eating junk and empty caloric foods such as chocolates, 
snacks, and soft drinks. These habits have increased the obesity which itself is a potent 
risk factor for CHD, hypertension, diabetes and dyslipidemia (Vergeer et al., 2010). The 
risk factors associated with MI have been summarized in Figure 1.6.                           
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1.6 Genetics factors 
 MI is heritable and among the leading cause of disability and deaths worldwide 
(Rosamond et al., 2008). It has been reported that if the first degree relative of a person is 
suffering from CHD the chances of that person getting the same problem increases 
manifold (Ryan et al., 1999). It is highly important for that person to make specific target 
oriented efforts to avoid the development of any other risk (Rosamond et al., 2008). 
Genetic factors contributing to MI susceptibility also include common Single Nucleotide 
Polymorphisms (SNP).  
1.7 Candidate and susceptible genes of MI 
 MI is polygenic trait inherited with positive family history. Genes associated with 
MI are found on many chromosomal regions; 9p21.3, 1p13.1, 2q36.3, 10q11.2 (Pasmant 
et al., 2007; Kathiresan et al., 2008; Mubotter et al., 2012). The following genes were 
selected to evaluate the associations with cardiac disease. 
1.7.1 CDKN2A 
 Cyclin dependent kinase inhibitor 2A and 2B are also known as p16 and p15 
respectively. These proteins are encoded by CDKN2A and CDKN2B genes. These genes 
are located on chromosome 9 (9p21.3). The role of chromosome 9p21.3 locus in 
pathogenesis of CHD may be due to presence of strongly associated SNPs found about 
100 kb from CDKN2A and CDKN2B genes (Samani et al., 2007). These proteins play a 
role in regulation of cell cycle and mutation can leads to atherosclerosis (Schunkert et al., 
2008). Function of these two inhibitors is to arrest the cell cycle at G1 and G2/S phases 
also block them from phosphorylation. So these genes are involved in playing an 
important role in cell aging, cell proliferation and apoptosis, leads to the formation of 
plaques inside arteries. Both genes were involved in the pathogenesis of atherosclerosis 
and MI (Pasmant et al., 2007).  
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1.7.2 ANRIL 
 CDKN2B-AS, also called as ANRIL (antisense non-coding RNA in the p16 locus) 
is a lengthy non-coding RNA comprising of 19 exons, its spliced part is a 3834 bp RNA. 
It is found within the p16/CDKN2A- p15/CDKN2B gene cluster, in the antisense 
direction. SNPs in this region alter the expression of ANRIL are significantly associated 
with number of diseases, including diabetes, cardiac disease and cancer (Mubotter et al., 
2012). Genes associated with chromosome 9p21 are shown in Figure 1.7. 
 
 
Figure 1.7: Chromosome 9, band p21 region. The location of the MI-associated region is shown 
in purple, annotated genes are shown in red and green, and the ANRIL anti-sense 
non-coding RNA is shown in blue. http://www.genecards.org/cgi-bin/carddisp.pl 
 
1.7.3 APOA5 
 Apolipoprotein A5 is encoded by gene APOA5. This gene is found on chromosome 
11 at long (q) arm on position 23 (11q23) (Figure 1.8). The APOA5 gene consists of 4 
exons. Its protein express in liver. The protein which is encoded by this gene regulates 
plasma triglyceride levels, a strong risk factor for cardiac disease. Apolipoprotein is 
associated with HDL-C and LDL-C. Mutation in this gene known to be associated with 
high triglyceride levels (Pennacchio et al., 2001). Many genetic studies had suggested 
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that variation in circulating lipid levels is determined by lipid metabolism related SNPs 
(Garcia et al., 2001; Samani et al., 2007).  
 
 
Figure 1.8: Chromosome 11, band q23 region. The location of the MI-associated region is shown 
in arrow. http://ghr.nlm.nih.gov/gene/APOA5 
 
1.7.4 PSRC1 
 PSRC1 (proline/serine-rich coiled-coil 1) is a potent protein encoded by PSRC1 
gene. Its function is to regulate the mitosis by microtubule assembly.  PSRC1 gene is 
located on chromosome 1p13.3. Its protein consists of 63 amino acids. 
Hypertriglyceridemia is associated with mutation in this gene (Kooner et al., 2008).  
1.7.5 CELSR2 
 Cadherin EGF LAG seven-pass G-type receptor 2 is also a protein of CELSR2 
gene.  This gene is located on 1p21 locus. Its protein acts as receptor which involved in 
cell mediated communication, signaling of cells, protein localization and cell 
differenciation (Kathirersan et al., 2008).  
1.7.6 HMGCR 
 HMG-CoA reductase is the enzyme involved in cholesterol synthesis. This 
enzyme is suppressed by cholesterol derived from degradation of LDL through LDL 
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receptors. Inhibitor of this enzyme induces the expression of LDL receptors, which 
increases the catabolism of plasma cholesterol and potent factor for atherosclerosis. This 
enzyme play a central role in cholesterol biosynthesis and elevates the risk of MI. 
HMGCR gene which is located on 5q13.3 locus, SNPs in this region may imbalance the 
plasma LDL-C (Kathiresan et al., 2009). 
1.7.7 NUTF2 
 Nuclear transport factor 2 is protein encoded by NUTF2 gene. This protein 
facilitates transport of ions, macromolecules and small molecules in to the nucleus. 
NUTF2 gene is located on chromosome16q22.1 (Willer et al., 2008). 
1.7.8 LDLR 
 Low density lipoproteins (LDLR) are receptors that involved in the uptake of 
LDL particles. These receptors play an important role in plasma lipoprotein balance. 
Genetic polymorphism in LDLR gene (SNPs) can alter its expression and participate to 
lipoprotein imbalance (Gao et al., 2013).  
1.8 Single Nucleotide Polymorphisms (SNPs) 
 SNPs are single base pair variations within the genome which are present at more 
than 1% frequency in human population (Risch, 2000). Variation of a single nucleotide 
A/C/G/T can alter the sequence of gene. It has been identified more than 1.4 million 
SNPs found in the human genome (Lander et al., 2001). Variants may be found 
throughout whole genome e.g. in introns, exons, promoter (Tokuhiro et al., 2003), 
intragenic regions and splicing sites (Betticher et al., 1995). Some SNPs do not occur in 
coding region of genes. A SNP that is found in coding region can directly affect the 
relevant protein by changing the amino acid (Livingston et al., 2004). However, SNP in 
promoter region may also affect the gene expression (Drazen et al., 1999). Many 
multifactor diseases such as diabetes, cancer, mental illness and heart disease are 
influenced by SNPs pattern in associated gene (Alfredo et al., 2007). The genetic 
polymorphisms may speculate an individual to be more susceptible to plaque formation, 
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increased lipid levels and thrombus formation (Wung, 2002). Risk factors for disease 
onset are influenced by genetic variants which could act by themselves or in combination 
with other lifestyle or genetic factors. Genetic variants that influence these risk factors 
may also be associated with onset of MI (Kathirersan et al., 2008).   
1.8.1 Haplotypes 
 Collection of SNPs along a chromosome is known as haplotype. Alleles that are 
found close to each other in a chromosome incline to be inherited together more than 
expected by chance. This phenomenon is known as Linkage Disequilibrium (LD). 
Polymorphisms which are in strong LD could not be getting apart even by recombination 
or mutation and thus transfer together in the next generation (Gabriel et al., 2002). 
Haplotype based association analysis have LD information from multiple markers, thus 
are powerful tool for gene mapping (Zaykin et al., 2002). 
1.9 Case-control association study 
 Genetic variants of complex diseases can be determined by association studies 
and linkage analysis (Daly and Day, 2001). Linkage analysis describes that region of 
genome with particular disease inherited within families (Bush and Moore, 2012). While 
in case control association studies the significant difference in allele and genotype 
frequencies between patient and control are taken as evidence for the involvement of 
allele in causing disease. There are many advantages of using case control association 
pattern of studies; cases and control are easy to enroll for sampling than family based, 
late progression of diseases can be studied, very large number of samples can be recruited 
for study and unreleated control increase strength of study for genetically related 
individuals (Daly et al., 2001; Cardon and Palmer, 2003). 
1.10 Economic burden of MI 
Majority of South Asians live on or below the poverty line with lack of healthcare 
systems or services, absence of National Welfare Programs and no provision of health 
insurance for this population (Jha, 2011). The poor people cannot afford to pay for 
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healthcare services. Cost greatly influences complication of CHD (Suhrcke et al., 2006). 
The low and middle income people are facing the socioeconomic burden to get their 
treatments (Nugent, 2008). Expenses of diagnosing the heart diseases through ECG, 
blood biomarkers, angiography, Computed Tomography (CT) scan and echocardiograph, 
etc. are very high. While, the main economic burden of cardiac disease is faced by a 
person at the time of heart surgery. The treatment of heart disease is a continuous process 
till end of their lives; patients have to consult their physicians every month, monthly 
medicine as well consultant charges are also difficult to afford (Zagrosek et al., 2011). 
When analysis of health expenditure was compared with household income in Pakistan 
depicted that ideal treatment is unaffordable for average patients (Nishtar, 2002). It has 
been reported burden of CHD is shifted towards the low socioeconomic strata in Pakistan 
(Gupta and Verma, 2006). One- third of Pakistani population is living in poverty; they 
cannot afford the increasing burden of such costly disease. Cost of treatment and 
diagnostic tests are very high and not affordable by poor people (Jones et al., 2009) 
Previous study of Pakistani population reported that treatment cost of heart disease runs 
into millions (Gaziano et al., 2010). 
1.11 Aims and objectives 
 Current study evaluated SNPs in associated genes that may play significant role in 
the onset of MI. Identification of genes responsible for susceptibility to MI will be 
helpful for understanding pathophysiology of the disease, in selection of suitable 
treatment and gene therapy. In addition SNP database will also be helpful for early 
diagnosis and detection of the disease.  
The major objectives are as follows:  
 To study demographic characterisitics of MI in different districts of North Punjab, 
for the better management of disease.  
 To evaluate the SNPs in candidate genes that may play significant role in the 
onset of MI. 
 
19 
 
CHAPTER 2 
LITERATURE REVIEW 
 Cardiac disease was reported as leading cause of worldwide mortality (Gupta et 
al., 2008). The European Society and American College of Cardiology has defined MI 
(Christenson and Christenson, 2013) as cell death of myocardium which can be detected 
by the imbalance in biochemical markers (troponins) or pattern of ECG changes. It was 
reported that almost 1.5 million people suffer from MI annually in the United States 
(Siddiuqi and Kayani, 2000; Eyre et al., 2004). The Pathophysiological triggering 
mechanisms for the onset of MI has been reported from last few decades (Sari et al., 
2009). The prevalence of heart disease increased with the advance age and differs within 
geographic, racial, socio demographic and ethnic groups (Rebecca et al., 2005).  
High risk of MI had been demonstrated in South Asian population and was 
reported the leading cause of deaths in developing countries including Pakistan (Chadha 
et al., 1990; Hafizullah et al., 2010). It was revealed that deaths due to MI in South Asian 
countries were 5-10 years earlier than other regions of the world (Yusuf et al., 2004) 
while, high risk of MI in younger age was determined by the levels of related risk factors 
(Enas and Senthilkumar, 2001). Different aspects of cardiac disease studied in 52 
countries among Asia, South America, Europe and Middle East found to be associated 
with various risk factors such as smoking, hypertension, history of diabetes, stress, 
alcohol intake, and physical inactivity (Roeters et al., 2002; Yusuf et al., 2004). The 
knowledge of simple conventional risk factors are not enough because of early 
occurrence of heart disease among South Asians therefore it was suggested both genetic 
as well as non conventional risk factors may play important role in the onset of disease at 
an early age (Ezzati et al., 2003). 
2.1 Risk factors associated with MI  
 The prevalence of MI risk factors in many countries reached on peak levels. 
Mackay and Mensah. (2004) depicted the global percentage of risk factors involved in the 
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onset of CHD was as follows; smoking (12%), obesity (7%), hypertension (9%) and 
dyslipidemia (7%). In addition 75% of the cardiac disease burden implying that heart 
patients have one or two of these risk factors. The strength of risk factors with disease 
susceptibility varies between populations. 
2.1.1 Age   
It has been reported 29% MI cases were found at the age of 80 years in developed 
countries (Reikvam and Hagen, 2002). On the other hand in developing countries mean 
age of MI patients range from 55-60 years (Bogousslavsky, 2001). The young population 
with MI at the age of 53 years was also found in South Asian population (Yusuf et al., 
2004). 
2.1.2 Obesity  
 Obesity is major health problem worldwide (Bray and Bouchard, 2003). It is 
associated with heart disease (Poirier et al., 2006). It was reported that 21% cardiac 
diseases were due to obesity globally (Lavie et al., 2009). Average BMI in people of 
Brazil was recorded 25–26 kg/m2 for females and 23-24 kg/m2 for males (Anjos et al., 
2013) while in Canada and USA above 27 kg/m2 was recorded for both females and 
males (Reaven and Laws, 1999). The 19.8% US people of young age were obese 
(Mokdad et al., 2002) whereas, 13.2% males and 22.6% females were overweight in 
Pakistan (Pappas et al., 2001; Nanan, 2002; Afridi and Khan, 2004). National 
representative survey of Pakistan has reported 25% of Pakistani people to be overweight 
and 10.3% were obese (Humayun et al., 2009). Obesity increases strain on the heart, 
raises blood pressure, cholesterol and increases diabetic risk (Eckel, 1997). 
2.1.3 Hypertension  
Van den Hoogen et al. (2000) investigated  connection of heart disease with high 
blood pressure in six different populations (Japan, Greece, Italy, Finland, Yugoslavia and 
Netherland) around the world and found greatly increase in mortality of cardiac disease 
due to hypertension. The worldwide prevalence of hypertension was 972 million (26.4%) 
in year 2000, of which two out of three belongs to developing countries (Kearney et al., 
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2005; Sultana et al., 2010). According to National Health Survey of Pakistan 1990-1994 
the prevalence of hypertension in Urban areas was 21.5% (one in every three persons of 
age of 45 years) and only less than 3% of hypertensive patients had their blood pressure 
around normal range of 140/90 mmHg (Aziz et al., 2005). However, 43.68% cardiac 
disease in Pakistan was due to hypertension (Khan et al., 2005). In Pakistan estimated 
average systolic blood pressure of people with 30 years of age was 130-140 mm Hg 
(Syed et al., 2008) whiles in India 120-130 mmHg (Adler et al., 2000) and 120 mm Hg in 
Thiland (Mackay and Mensah, 2004). It was also reported that people with high blood 
pressure have early MI symptoms due to hypertrophy which is associated with 
hypertension (Rosendorff et al., 2007). 
2.1.4 Diabetes    
Diabetes mellitus and glucose intolerance are major risk factors for CHD in Asia 
(Steinberger and Daniel, 2003). Prevalence of diabetes has been increasing throughout 
Asia (Ramachandran et al., 2008). Risk of diabetes varies between populations from 
7.2% among Australians to 21% among younger Arabians (Dunstan et al., 2002; Malik et 
al., 2005). It was reported the prevalence of diabetes in peoples with aged ≥ 27 years was 
5-5.9% in Pakistan and India, 15% in Qatar, 14.9% in Greece and < 5% in China 
(Mackay and Mensah, 2004). In Libya 48.2% hospitalize MI patients were diagnosed 
with diabetes (Abduelkarem et al., 2012). Furthermore, in Britain 10.5 - 30.0% MI 
patients were diabetics (Wilkinson et al., 1996; Alnemer et al., 2012).  
The prevalence of type 2 diabetes mellitis in cardiovascular patients in Peshawar, 
Pakistan was reported 23.00% (Khan et al., 2005). INTERHEART study among 52 
countries reported 18% diabetes cases among MI patients (Yusuf et al., 2004). In the 
terms of absolute number of people with diabetes; Pakistan, India and Bangladesh were 
three of top ten countries globally (Wild et al., 2004). South Asians have higher 
prevalence of type 2 diabetes and early onset of heart disease was reported despite of 
normal BMI in diabetic patients (Diaz et al., 2007; Joshi et al., 2007). Diseases, type 2 
diabetes and cardiac are interlinked (Enas and Mehta, 1995). Diabetes had been reported 
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to be associated with left ventricular dysfunction and take part in progression of coronary 
atherosclerosis (Wilkinson et al., 1996).  
2.1.5 Cholesterol  
High cholesterol in serum was reported to be critical risk factor for CHD in Asian 
population (Okamura et al., 2003). The recommended level of total cholesterol for 
average healthy individual in Asians is ≤ 240 mg/dl, where LDL-C level should be ≤ 160 
mg/dl and HDL-C level should be 40 mg/dl (Battinelli, 2007). Abnormal lipid parameters 
(LDL-C, HDL-C and triglyceride) are powerful predictors of atherosclerosis and leads to 
heart attack (Ballantyne et al., 2001; Gabriel et al., 2008; Sigdel et al., 2012). The risk of 
heart disease increases significantly by 1 mmol/L (40 mg/dl) rise in total plasma 
cholesterol (Critchley et al., 2004). The mean plasma cholesterol level 117 mg/dl (6.5 
mmol/L) was reported in Chinese people (Wu et al., 2004). People of many countries had 
higher cholesterol even greater than 6.5 mmol/ L (Jousilahti et al., 1998), such as mean 
plasma cholesterol level 208 mg/dl (11.5 mmol/L) was recorded in America (Metz et al., 
2000). Both LDL-C and HDL-C have antagonistic association with MI risk where HDL-
C negatively and LDL-C being positively associated with MI (Di Angelantonio et al., 
2009).  
South Asians have higher levels of LDL-C and lower HDL-C levels as compared 
to other populations (Kulkarni et al., 1999; Bhalodkar et al., 2004). Lipid abnormalities 
were found especially in Pakistan and Bangladesh (Bhopal et al., 1999; France et al., 
2003). It has been recommended less fat intake by diet can reduce total blood cholesterol 
(Hooper et al., 2012). Both genetic and environmental factors are involved in 
hypercholesterolemia (Bhatnagar et al., 2008). The West of Scotland Coronary 
Prevention Study (WOSCOPS) found lowering cholesterol levels can reduce the risk of 
heart disease in those peoples having LDL-C concentration greater than 73 mg/dl 
(Rosamond et al., 1998).  
Triglycerides had shown to play a key role in pathogenesis of MI (Hooper et al., 
2012). Its level in plasma more than 150mg/dl is regarded as high (Sigdel et al., 2012). It 
had been found triglyceride rich lipoproteins are the cause of endothelial dysfunction by 
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entering into atherosclerotic plaques (Rapp et al., 1994; Carantoni et al., 1997) and also 
stop the cholesterol transport into liver (Palmer et al., 2004). The products of lipid 
peroxidation were found to be involved in plaque disruption (Hodis et al., 1994).  
2.1.6 Smoking  
There is a relationship between smoking and high cholesterol levels; this may 
reflect the increased intake of cholesterol with diet among smokers (Hebert and Kabat, 
1990). Smoking as a very potent risk factor associated with dysfunction of endothelium 
and contributes to the onset of MI even in those individuals with minimal atherosclerosis 
(Yusuf et al., 2004). The incidence of smoking have been decreasing in European 
countries (Fuster and Kelly, 2010) however, has not been the case in Asian population 
where 40 - 60% incidence of smoking was recorded (Yang et al., 1999). Highest smoking 
rate in Chinese and South Asians (Hermalin and Lowry, 2011) was reported whereas, 
smoking was less common in South Americans (Li et al., 2007). The 62.6% people were 
found smokers in Libyan population in the year 2012 (Abduelkarem et al., 2012). It was 
demonstrated, if current trend of smoking persist will cause deaths of 8 million people 
worldwide each year by 2030 and of 80% deaths will be from developing countries 
(Kreatsoulas and Anand, 2010). Different studies in China (Loke et al., 1997), Brazil 
(Levy and Thom, 1998), Lebnan (Monteiro et al., 2004) and India (Malhotra et al., 2003) 
have reported 40% of patients with MI were smokers for most of the time in their lives.  
According to local study estimates the prevalence of smoking in Pakistani 
individuals aged ≥ 8 years was 14.2% (95% CI: 13.6-14.8) and 19.4% (95% CI: 19.08-
19.72) among group aged ≥ 15 years (Nasir and Rehan, 2001). The smoking was much 
prevalent among urban areas (15.2%) than rural areas (13.7%) of Pakistan (Alam et al., 
2008). Smoking badly affects the lining of arteries which can double the risk of heart 
attack (Mehta and Eagle, 1998).  
2.1.7 Hyperhomocysteinemia  
Mild hyperhomocysteinemia (homocysteine level in plasma between I5-25 
umol/L) is another factor which has positive association with heart disease (Donner et al., 
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1998; Iqbal et al., 2006). Higher homocystein is a potent risk factor for atherosclerosis 
which leads to heart attack (Mc Cully, 2007). The nutritional deficiency of folate and 
vitamin B6 is the major cause of hyperhomocysteinemia in the Pakistani population 
(Iqbal et al., 2006; Yakub et al., 2010). The inadequacy of these vitamins in Pakistan may 
be due to minimum use of fresh fruits and vegetables, overcooking of food and high 
prevalence of parasitic enteric infections (especially amoebiasis and giardiasis) (Laghari 
et al., 2010). 
2.2 Knowledge of risk factors 
The level of knowledge for MI varies among populations. It had been found US 
whites have high knowledge about onset and consequences of the disease (Ford and 
Jones, 1991). However, in South Asian families who inhabit in UK had lower awareness 
about cholesterol and dietary contents than native white people (Rankin and Bhopal, 
2001). The less education is major factor for lack of knowledge among South Asians 
(Kandula et al., 2010). Less than 20% individuals have knowledge about risk factors of 
MI and its consequences in Pakistan (Dodani et al., 2004).  
2.3 Treatment cost  
Coronary heart disease is one of the costly diseases showing a huge economic 
burden on health care system. It had been reported in USA direct and indirect expenditure 
of heart disease in 1995 was 17,532 US$ annually/patient (Russell et al., 1998). Tarride 
et al. (2009) investigated treatment cost in eight different countries ranged from US$ 
9512 (Belgium) to 18293 US$ (Austria), while in USA treatment cost as high as 32,975 
US$/year/patient. The cost of MI treatment was 10 to 20 times greater than angina 
pectoris (Stewart et al., 2003). In Pakistan 75% people living in poverty are unable to 
afford the high expenditure (diagnosis, treatment, surgery) of such costly disease. 
Sehrish. (2011) demonstrated even diagnostic tests of cardiac disease in Pakistan are in 
the range of 40,000 to 50,000 PKR (405.3-506.7 US$/ patient).  
 
25 
 
2.4 Genetic factors 
 Several genes and genetic loci had been reported to showing association with 
onset of MI (Helgadottir et al., 2007; Saxena et al., 2007; Shen et al., 2008). Total eight 
Genome Wide Association Studies (GWAS) have been published for risk factors 
association at P ≤ 10-5 with CHD or MI. The remainder genetic studies have examined 
markers associated with CHD including HDL-C, LDL-C, C reactive proteins and 
coronary artery calcification (Mc Pherson et al., 2007; Kathiresan et al., 2009; Samani et 
al., 2009).   
2.4.1 Genetic studies of 9p21.3 locus and related SNPs 
 Genetic variants of 9p21.3 region have great importance in molecular genetics 
consisting of; CDKN2A, CDKN2B and ANRIL genes (Samani et al., 2007. The risk 
haplotypes at 9p21.3 locus [(rs10757274-G), (rs4977574-G), (rs2891168-G), (rs2383206-
G), (rs2383207-G), (rs1333049-C)] were shown to be overlaped with ANRIL gene 
(Broadbent et al., 2008). 
GWAS have depicted strong association of chromosome 9p21 with susceptibility 
of MI (Helgadottir et al., 2007). Two SNPs in chromosome 9p21 locus (rs10757274 and 
rs2383206) were strongly associated with MI in Canadian cohort as well as five white 
cohorts (Mc Pherson et al., 2007). Two other SNPs at the same locus; rs10757278 and 
rs2383207 were studied in Iceland, German and British populations (Helgadottir et al., 
2007; Samani et al., 2007; Yamada et al., 2008). Many independent case-control 
association studies have pointed out significant role of chromosome 9p21.3 locus with 
onset of MI in Sweden (Saxena et al., 2007), Finland (Scott et al., 2007), UK (Zeggini et 
al., 2007) and Italian population (Shen et al., 2008). Another variant rs1333049 (risk 
allele C) was demonstrated playing a key role in the formation of atherosclerotic plaque 
(Ye et al., 2008) and associated with onset of cardiac disease (Schunkert et al., 2008). 
Polymorphism at 9p21.3 locus was not associated with onset of MI in African Americans 
(Dehghan et al., 2008). The opposite results were may be due to ethnicity difference 
(Horne et al., 2008).  
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2.4.2 Genetic studies of other loci related to cardiac disease 
Some variants at chromosome 1p13 (CELSR2, PSRC1 and SORTI) were found to 
be associated with early onset of MI (Samani et al., 2007; Wallace et al., 2008; 
Kathiresan et al., 2009). SORTI gene had been implicated playing a key role in insulin 
resistance (Kaddai et al., 2009). In addition to this locus Lipoprotein Lipase (LPL) gene 
at 8p21 locus has also been replicated in multiple GWAS was associated with HDL-C 
and triglyceride levels (Kathiresan et al., 2008; Willer et al., 2008). Chromosomes 6q24 
(rs12526453) and 10q11 (rs1746048) were investigated to be linked with MI (Huang et 
al., 2013). 
Mutation in Low-density lipoprotein receptor (LDLR) and protein convertase 
subtilisin/kexin type 9 (PCSK9) at 19p13 involved in recycling of LDL receptors, leading 
to autosomal dominant hypercholesterolemia (Kathiresan et al., 2009). Genetic variants 
(rs2569556, rs12084215, rs565436 and rs23862269) in LDLR and PSK9 regions have 
been shown to be significantly associated with plasma higher LDL-C level in Malaysia 
(Lye et al., 2013). Haplotype analysis of these genetic loci reported significant 
association of higher LDL-C levels with MI (Bostom et al., 1996). 
Apolipoprotein E (APOE) gene is important predictor for LDL-C transport and 
metabolism, so responsible for removal of cholesterol from the blood (Lahoz et al., 
2001). SNPs associated with APOE affect the cholesterol metabolism, which in turn play 
a potential role in onset of heart disease particularly heart attack. It has been depicted 
polymorphism in APOE gene was associated with higher risk of MI (Wilson et al., 1994; 
Lahoz et al., 2001).  
Methylenetetrahydrofolate reductase (MTHFR) is an enzyme encoded by gene 
MTHFR has a key role in conversion of hemocystein (toxic amino acid) in to methionine. 
Mutation in MTHFR can cause plasma higher hemocyctein level associated with 
increased risk of MI (Christen et al., 2000). Genetic variant rs1801133 (677 C-T) of 
MTHFR gene (chromosome 1) had been depicted to be associated with reduction of 
MTHFR activity (Ueland and Rozen, 2005). Polymorphism of 677 C-T was associated 
with disease susceptibility (Gallagher et al., 1996; Kluijtmans et al., 1996; Helgadottir et 
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al., 2006). A meta-analysis from 40 studies showing; polymorphism of SNP rs1801133 in 
MTHFR gene with genotype TT had an odd ratio of 1.16 as compared to CC genotype 
(Klerk et al., 2002). Another meta-analysis from 80 studies showed variant in MTHFR 
gene associated with high risk of MI with an overall odd ratio of 1.14 for TT genotype, in 
addition odd ratio for population of Australia, Europe and North America was 1.0, 
whereas for Asia was 1.23. These results demonstrated 677C-T polymorphism is 
associated with risk of MI in Asian population, but not in Australia, North America and 
Europe (Lewis et al., 2005). Genetic regions reported to be associated with onset of MI or 
related phenotypes in GWAS are shown in Table 2.1. 
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Table 2.1: Overview of the genes associated with myocardial infarction or coronary artery disease that have been 
identified by GWAS 
Chrom 
segment 
Gene Function SNP Population Reference 
1p13.3 PSRC1, 
CELSR2, 
SORT1, 
MYBHL 
 
LDL-C 
increase 
rs599839 
 
Caucasian 
UK 
China 
Finland/Sweden/France 
Germany 
American Caucasians 
Samani et al., 2007 
Sandhu et al., 2008 
Huang et al., 2008 
Karvanen et al., 2009 
Kleber et al., 2010 
Wang et al.,  2011 
 
1q41 
 
MIA3 
Collagen 
procession 
 
rs300861 
rs17465637 
 
Caucasian 
American Caucasian 
 
Samani et al., 2007 
Wang et al., 2011 
5q13.3 HMGCR Cholesterol 
biosynthetic 
pathway 
rs3846663 
 
Americans 
Kosre  
 
Chen et al., 2009 
Lowe et al., 2009 
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Table 2.1 continue 
Chromoso
me segment 
Gene Function SNP Population Reference 
11q23 APOA5 Triglyceride 
regulation 
rs1558861 
rs10750097 
rs3135506 
rs662799 
rs662799 
rs651821 
Europe 
China 
Italy 
Pakistan 
Hong Kong 
India 
Wang et al., 2008 
Willer et al., 2008 
De Caterina et al., 2011 
Saleheen et al.,2010;  
Jiang et al., 2010 
Li et al., 2007; Liu et al., 2010 
14q13 PSMA6 
Inflammatory 
pathway rs2277459 
rs17458312 
rs1048990 
rs2277461 
Japan 
UK 
China 
East Asia 
Ozaki et al., 2006 
Bennett et al., 2008 
Liu et al., 2009 
Wang et al., 2011 
20q11 MMP9 Breakdown of 
extracellular matrix, 
polymorphism 
results  in 
inflammation of  
aorta 
rs3918242 
rs2664538 
Europe 
Turkish 
Horne et al., 2008; Willer et al., 
2008 
Alp et al.,  2009 
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Table 2.1 continue 
Chromosome 
segment 
Gene Function SNP Population Reference 
9p21.3 CDKN2A
, 
CDKN2B
, ANRIL, 
 rs4977574 
rs1333049 
rs10757283 
rs2891168 
rs10757278 
rs2383206 
rs2383207 
rs10757274 
rs10811656 
Iceland 
South Korea 
Caucasian 
British 
Italy 
Asian Indian 
Pakistan 
China 
America, Caucasians 
USA, Sweden, Finland,  
Spain, and Italy 
Finland and Sweden 
South Asia 
 
Helogodottir et al., 2006 
Shen et al., 2007 
Samani et al., 2007 
Burton et al., 2007 
Shen et al., 2008 
Maitra et al., 2008 
Saleheen et al., 2010 
Wang et al., 2011 
Abdullah et al., 2008 
Kathirersan et al., 2008 
 
Ripatti et al., 2010 
Peden et al., 2011 
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Table 2.1 continue 
Chromosome 
segment 
Gene Function SNP Population Reference 
6q24 
PHACTR1 Coronary 
calcification 
rs12526453 
rs9349379 
USA, Sweden, Finland, 
Spain, and Italy. 
Europe 
Kathiresan et al., 2009 
 
Schunkert  et al., 2011 
6q26 LPAL2, 
LPA, 
SLC22A3 
It encode 
protein which 
play role in 
lipoproteins 
pathway 
rs2048327 
rs3127599 
rs7767084 
rs10755578 
Northern Europe 
China 
Tregouet et al., 2009 
Zhang et al., 2013 
19p13 LDLR Regulate 
LDL-C levels 
rs1122608 USA, Sweden, Finland, 
Spain, and Italy 
Europe 
Kathiresan et al., 2009 
Ripatti et al., 2010 
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CHAPTER 3 
MATERIALS AND METHODS 
 The study was conducted in two phases, in first demographic characteristics and 
economic burden of MI were studied. In second phase the association of genetics with MI 
was determined.  
3.1 First phase 
3.1.1 Data Collection 
 In this phase of study data was collected from six regions of north Punjab, 
Pakistan. Urban MI patients from developed areas (Lahore, Islamabad) and rural cases of 
developing areas (Faisalabad, Gujranwala, Gujrat and Sialkot) were included in this 
survey. The diagnostic criterioa (prescribed by the doctor or clinically diagnosed) was 
based on severe chest pain of 30 minutes duration, characteristic electrocardiographic 
patterns of MI and significant elevation of cardiac enzymes such as Creatine Kinase 
Myocardial Band (CK-MB). The study protocol was approved by ethical committee 
Board of Advanced Studies and Research Board (BASR). Participation rate of patients 
was 65%. Excluded subjects were 285 out of 800 because of incomplete data of variables. 
Thus 515 patients were included in this phase of study. Inclusion criteria were patients 
with MI as principal diagnosis and admission via CCU and emergency wards. A 
questionnaire was designed to collect data (Annexure I). The analysis was focused on 
identifying the socioeconomic status (education, employment status, income), life style 
(smoking, physical activity and dietary pattern), family history of MI and risk factors 
(diabetes, hypertension and hyperlipidemia) were obtained. All the subjects were 
assessed for blood pressure and body mass index [weight divided by square of height in 
meters (kg/m2)]. Overweight was defined as a BMI > 25 kg⁄m2 (Hwang et al., 2006). 
Hypertension defined as mean systolic blood pressure ⩾140 mm Hg or mean diastolic 
blood pressure ⩾90 mm Hg. Hyperlipidemia was defined as patients having cholesterol 
level ≥ 200 mg/dl. According to family income (monthly) patients were divided into three 
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categories as low income (≤ 10,000 PKRs), middle income (10,000-20,000 PKRs) and 
high income group (≥ 20,000 PKRs). Fasted blood samples (3ml-5ml) of all participants 
were collected by special staff and were sent to concerning laboratories of hospitals for 
lipid profile and blood sugar measurement. Those subjects having fasting glucose ≥ 126 
mg/dl were considered hyperglycemics and those having history of diabetes mellitus as 
well as using glucose lowering medicines considered diabetics. Diabetes defined as 
patients taking antihypertensive drugs or having fasting blood sugar ⩾7.0 mM. Disease 
treatment cost was expressed in Pakistani Rupees (PKRs) and for international level it 
was converted to US dollar at a rate of 98.50 PKRs =  1US$. 
3.2 Second phase (Genetic analysis) 
For second phase (genetic analysis) of the study, total of 384 Pakistani subjects 
(Central Punjabi population) consisted of each 192 MI patients and healthy controls were 
recruited and analyzed. Blood sampling was carried out from Punjab Institute of 
Cardiology and Jinnah Hospital Lahore Pakistan. The diagnostic criteria for patients were 
same as described above. The complete clinical and demographic history of all subjects 
was recorded. Control subjects were individuals without a history of CHD and were in 
good health. They were frequency-matched to patients by sex and age (in 5-year bands). 
This study was conducted as per Good Clinical Practice (GCP) guidelines (Declaration of 
Helsinki). Patients not willing to sign consent form and with previous illness associated 
with hepatic and renal failure, HIV, cancer were excluded from the study. 
3.3 Blood Sampling 
Blood was drawn after an overnight fast but within 48 hours of admission to the 
hospitals and before coronary angiography for genetic analysis. In second phase of study 
about 3 to 5 ml of blood was collected in EDTA coated tubes and was stored at 4.0oC for 
further process of DNA extraction. Fasting concentrations of total cholesterol, plasma 
triglyceride, and blood sugar were measured for cases and control at the laboratory of 
Punjab Institute of Cardiology Pakistan. 
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3.4 DNA extraction  
 DNA was isolated using modified extraction procedure (Sambrook et al., 1989). 
In the first step 500 μl of blood sample was mixed with 500 μl of TE buffer and 
incubated at room temperature for 15 min, centrifuge the sample at 25oC with 13500 rpm 
for 5-10 min. Then pellet was broken after discarding supernatants. Pellet was dissolved 
in 375 µl of 3M sodium acetate. Then 25 µl of 10% SDS and 5-10 µl of proteinase K (10 
µg/µl) were added and incubated at 37oC overnight in a shaking water bath. Chilled 
chloroform: isoamyl alcohol (24:1) was added. Mixed and centrifuged at 25oC with 
13500 rpm for 5-10 min. Three layers were visualized after centrifugation. The upper 
layer contained DNA. The DNA layer was carefully transferred into a new labeled 
eppendorf. Chilled absolute ethanol was added by gently inverting eppendorfs. The dried 
DNA pellet was dissolved into 50-100 µl low TE buffer, incubated in a shaking water 
bath at 70oC for 30 min. Detailed procedure is described in Annexures II. Concentration 
of DNA was measured by nanodrop method. 
3.5 Selection of Genes and SNPs 
 Selection of SNPs was based on the reported genetics association with MI from 
HapMap data bank and National Center for Biotechnology Information (NCBI) 
(http://www.ncbi.nlm.nih.gov). Those SNPs were selected from the genes which were 
reported to be involved in regulating plasma triglycerides, HDL-C, LDL-C or playing 
role in the enhancement of MI risk factors for example obesity, depression and 
hypertension. The list of 22 SNPs in 9 candidate genes chosen for determination of the 
genetic association between cases and control has been shown in Table 3.1.  
3.6 Oligonucleotide primers 
Primers for 1st and 2nd poymerase chain reaction (PCR) were designed using 
primer 3.input 0.40 (http//frodo.wi.mit.edu/primer 3) and supplied by Bio Basic, Canada 
(Table 3.2). The specificity of the primers were further examined and confirmed through 
sequence alignment of them with the human genomic reference sequence using BLASTN 
program and the fidelity of PCR amplicons was verified by agarose gel electrophoresis. 
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Table 3.1 Selected SNPs for myocardial infarction genetic association study 
SNP NO SNP ID chr Position Gene 
S1 rs4977574 9p21.3 22188574 CDKN2A/B 
S2 rs2891168 9p21.3 22188619 CDKN2A/B 
S3 rs2383206 9p21.3 22115026 CDKN2A/B 
S4 rs2383207 9p21.3 22115959 CDKN2A/B 
S5 rs10811656 9p21.3 22124472 CDKN2A/B 
S6 rs10757278 9p21.3 22124477 CDKN2A/B 
S7 rs1333049 9p21.3 22125503 CDKN2A/B 
S8 rs10757283 9p21.3 22134172 CDKN2A/B 
S9 rs1333047 9p21.3 22124504 CDKN2A/B 
S10 rs10757277 9p21.3 22124450 CDKN2A/B 
S11 rs10757279 9p21.3 22124630 CDKN2A/B 
S12 rs3135506 11 116662407 APOA5 
S13 rs1558861 11 116607437 APOA5 
S14 rs662799 11 116663707 APOA5 
S15 rs10750097 11 116664040 APOA5 
S16 rs599839 1P13.3 109818530 PSRC1 
S17 rs646776 1P13 109822166 CELSR2 
S18 rs3846663 5q13.3 7655726 HMGCR 
S19 rs2271293 16 67902070 NUTF2 
S20 rs6511720 19 11202306 LDLR 
S21 rs1537375 9 22116071 ANRIL 
S22 rs4986790 9 120475302 TLR4 
Chr =chromosome, SNP = single nucleotide polymorphism 
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Table 3.2 Primers used for sequencing and OLE 
 
SNPs 1st PCR Primers Sequence (5'- 3') 
Product 
size 
Nested PCR Primers Sequence (5'- 3') 
Product 
size 
Annealing 
Tm (◦C) 
S1 
  
F: ggcccacatcacctccttat 1696 F: ttgcttgctggttcccagag 797 56 
R: tagacgtgcccagctattgg R: tgaatggcatgttttccagcg 
S2 
  
F:  aagcaggtagcaggtagtgc 1705 F:  ccatgctttctgaaacaacacg 795 58 
R: ccagctccccgtcaattcat   R:  cgtgcccagctattggctat 
S3 
  
F:ctgcttgcctcacaggatct 1718 F:gcaagccacatgcccctaag 400 60 
R:gtttatgcatgcgtcctggc R:ttaagggacaggaagaatcaggac 
S4 
  
F: acacttatgccaggacgcat 1321 F:cagcagggaagtgattccga 741 56 
R: tgggccaagttgtctcaagt R:ggggagtacagactaccttgtg 
S5 
  
F: aggtgctgctattaggatggc 1216 F:  tgaggtcgcaactaaaagcca 559 56 
R: ggcaggccacacttgtgtaa R:  tccacgctgttcccaagtag 
S6 
  
F: aggtgctgctattaggatggc 1216 F:  tgaggtcgcaactaaaagcca 539 58 
R:  ggcaggccacacttgtgtaa R:  tccacgctgttcccaagtag 
S7 
  
F:  cctggctacttgggaacagc 1793 F:  gaccttcatgctattttgaggag 591 58 
R:  tgctctcaactaaaccttggc R:  acaatatgtctggcagatcttgga 
S8 
  
F:  tctgagagccacagttgtcc 1774 F:  aaccttcagccacctctctg 779 56 
R: tcctgattaaccccaaccagc R:  tctctttctgtgtgggatgc 
S9 
  
F: aggtgctgctattaggatggc 1710 F:  tgaggtcgcaactaaaagcca 760 56 
R:  ggcaggccacacttgtgtaa R:  tccacgctgttcccaagtag 
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Table 3.2 continue 
SNPs 
NO 
 
 
1st PCR Primers Sequence (5'- 3') 
 
 
Product 
size 
 
Nested PCR Primers Sequence (5'- 3') 
 
Product size 
 
Annealing 
Tm (◦C) 
S10 
  
  F: aggtgctgctattaggatggc 1710  F:  tgaggtcgcaactaaaagcca 760 60 
  R:  ggcaggccacacttgtgtaa R:  tccacgctgttcccaagtag 
S11 
  F: aggtgctgctattaggatggc 1710  F:  tgaggtcgcaactaaaagcca 760 56 
  R:  ggcaggccacacttgtgtaa R:  tccacgctgttcccaagtag 
S12 
  
F: ggtcttgctcaaggctgtct 1128 F:gggcgctaaagagcccaggat 650 58 
R:gaactgttcctggggtctgg R:tagcctccttgactcacctaggtca   
S13 
  
F: tgggaatccgtggtgtgatg 1080 F: ctctctctccttcacaaggaact 601 58 
R: cagaaccaagcgtgacaacc R:  ggaggaaaaggatgcaggacc   
S14 
  
F: tgcttcccaggagctttacg 1769 F: agcttcactacaggttccgc 529 60 
R: ggacaggccacttgatctcc R: taaaggctcagggaatgccg   
S15 F:gggcccctctcttacacaac 1376 F:ccttcttcggccttcacctt 775 58 
  R:aaggtgaaggccgaagaagg  R:gcccgagctggcctacattt   
S16 F: gggaggccctacaccaaatc 1392 F: gaccaacctgaccaacatgg 539 60 
  R: ccagggacaggaggaagaga  R:tggacatttccacgtgagcg   
S17 F:  tccaaccagcctctcaatgc 1216 F:  gggcaaagagaagtgggact 539 56 
  R: ccaggtgtttgctcagttgc    R:  aggtggctgaacaagaaggg   
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Table 3.2 continue 
SNPs 
NO 
 
 
1st PCR Primers Sequence (5'- 3') 
 
 
Product 
size 
 
Nested PCR Primers Sequence (5'- 3') 
 
Product 
size 
 
Annealing 
Tm (◦C) 
S18 F: atatcagctgcaccatgcca 1347 F: tcaggcatagagtccacaagc 698 56 
  R: gtcgggctattcaggctgtc  R: tgccaatgctgccataagtg   
S19 F:  gttctgcccttgaaggctgt 1769 F:  tgaccccatgggtatccaga 529 56 
  R: cagaaggggtgggaaaggag  R:  ccttcccacgtaaggcatga   
S20 F:  tcacaaaggcgacgacaagt  1707 F: caagggggttggctttgact 669 60 
 
R:  gctgctggtcggttacatct  R:tctaagtgaaggcttgcggt   
S21 F:  caaggagggaagactgggga  1483 F:  cagcagggaagtgattccga  790 58 
  R:  aggaccttttatggcctcagc  R:  tccgtttgatatacaccgtttgag   
S22 F: tattgcacagacttgcgggt 1348 F: tccatcgtttggttctgggag 690 58 
  R: tgaggaccgacacaccaatg  R:cctggaaagaattgccagcc   
OLE=one base label extension, F = forward primer, R = Reverse primer, Tm = temperature, bp = base pair
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3.7 Genotyping by OLE and verified by sequencing 
 All genotyping {Sequencing and One Label Extension (OLE)} was performed at 
Applied Genomic Center of Hong Kong University of Science and Technology (HKUST) 
Hong Kong. Following the procedure described below. 
3.7.1 Master Mix (5x) composition for PCR  
 H2O                                 360 µl 
 dNTPs (10mM)            100 µl 
 MgCl2(0.2M)                 40 µl 
 10x buffer                     500 µl 
3.7.2 1st PCR 
 A 96 well plate was used for optimization process (Annexures III). After 
optimization DNA fragments for each primer were amplified through 1st PCR. 
Amplification was carried out in a 20 μl PCR mixture containing 50-60 ng of genomic 
DNA, 75 nM of each primer (PCR primers are listed in Table 3.2), 50 nM of each 
deoxyribonucleotide triphosphate (dNTPs: Promega USA U1515), 2.5 mM magnesium 
chloride (MgCl2, Sigma: M2670) and 1U Taq DNA polymerase (Amersham Bioscience, 
Uppsala, Sweden). The program of PCR consisted of one cycle of initial denaturation at 
95°C for 5 min, followed by 30 cycles of 30 seconds at 95°C, 30 seconds at 56°C 
(gradient PCR), 2 min at 72°C and final extension step at 72°C for 8 min (Applied 
Biosystem thermal cycler model# 9902, Singapore). As shown in Figure 3.1. 
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(a) (b)    
  
  
 
                                  (c) 
 
Figure 3.1: (a) 96-well PCR plate (b) samples loading (c) seal plate with foil seal after 
loading reaction mixture 
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3.7.3 Purification of 1st PCR product 
 Absolute ethanol was used for the purification of PCR products and the mixture 
was kept at -20°C for at least 1 hour. Take out PCR product and after centrifugation at 
3500 rpm (eppendorf 5810 centrifuge, Germany) for 30 min at room temperature, the 
precipitates were washed out two times with 70% ethanol and centrifugation was done 
between washes at 3500 rpm for 20 min (Figure 3.2). Vacuum was applied for at least 20 
min until wells were completely dry. 20 µl H2O (Millipore USA) was added to elute the 
purified PCR product. Heat the product in PCR machine by run the program 5510 (5m at 
55°C) and was stored at -20°C until use. 
 
 
Figure 3.2: Centrifuge machine used for short spin and for purification of PCR product 
 
3.7.4 Nested PCR (2nd PCR) 
 DNA fragment was amplified through nested PCR using genomic DNA as 
template in the first round of amplification (Lo et al., 2007) and using amplicons from the 
first round as the templates in the second round of amplification.  
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3.7.4.1 Nested PCR (Ingredients of reaction mixture) 
       PCR Components              volume of each well                         volume of half plate 
 Forward primer                                                                   3.25 µl (Each primer) 
 Reverse primer                                                                    3.25 µl (Each primer) 
 Master mix                       4   µl                     50x                     200 µl 
 H2O                                                                       14.5µl             ________               725 µl 
 Taq pol                              0.3 µl                                          15 µl 
 DNA                                         0.6 µl   
                                                        20 µl                                            1000µl 
 
 Amplification of DNA fragment was carried out in a 20 μl PCR mixture 
containing 50-60 ng of genomic DNA, 125 nM of each primer , 200M of each dNTPs 
(Promega USA U1515), 2.5 mM MgCl2 (Sigma: M2670), 10mM Tris HCl, 50mM, 
Potassium Chloride (KCl) and 1U Taq DNA polymerase (Amersham Bioscience, 
Uppsala, Sweden). PCR amplification consisted of denaturation at 95°C for 5 min, 
followed by 30 cycles of 30 sec at 95°C, 30 sec at 56°C, 1 min at 72°C and finally at 
72°C for 8 min. The annealing temperature was modified according to different SNPs for 
2nd PCR, the protocol remained same except in the final step one min instead of 2 min at 
72°C. The ethanol purification was carried out (as described above) and amplicon was 
stored at 4°C till further use (DNA sequencing and OLE assay).                             
3.7.5 Agarose Gel Electrophoresis 
 It was used to determined the PCR products (presence or absence) and quantify 
the size (length of the DNA molecule) of the product (Annexure IV). 
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3.7.6 Direct DNA sequencing 
 SNP genotyping was executed by direct sequencing of nested PCR Product 
(Figure 3.3). Each sequencing reaction contained 0.75 µl of Big Dye (Applied Biosystem 
UK 1201096), H2O (Millipore, USA) 14.5 µl, sequencing buffer 3.00 µl (Applied 
Biosystem UK 1203142), 240nM forward/reverse primer (refer to Table 3.2 for 
sequencing primer sequence) and 1.5 µl purified PCR product. Each cycle of sequencing 
reaction consisted of initial denaturation at 96 °C for 1 min, followed by 25 cycles each 
of 10 sec at 96 °C, 5 sec at 50 °C and 4 minutes at 60 °C. After sequencing reaction 
plates were taken out and short spinned. 
 
 
Figure 3.3: Genetic analyzer 
 
3.7.6.1 Purification for sequence reaction and sequencing 
 Ethanol precipitation was carried out to clean-up the post-sequencing mixture. 
After sequence reaction 45µl of 100% ethanol was added to each well and placed at -
20◦C for 1 hour to precipitate the DNA. The plate of sequence reaction was taken out and 
placed on bench for one minute. The centrifugation was done at 3500 rpm for 30 minutes 
at room temperature to get the precipitates of DNA. Precipitates were washed three times 
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with 75% ethanol at 3500 rpm for 20 min. The plate was rapped with a piece of paper, 
spin down all solution for 7 sec. Each plate was dried for 20 min in a Vacuum pump. 
Each air-dried sequencing sample was dissolved in 10 µl Hi-Deionized Formamide [Hi-
Di (Applied Biosystems Inc)]. After adding Hi-Di the plate was sealed and denatured at 
95°C for 5 min in 96-well thermo cycler then take out and quickly transferred to coolers 
which were stored at -20°C (Figure 3.4). At least for 3-5 min the plate was placed in 
cooler and settled in the rack, adjusted in genetic analyzer to sequence the fragment of 
interest (Model 3130 Genetic Analyzer (Applied Biosystems UK). 
 
(a)                                                                                           (b) 
 
 
                    
Figure.3.4: (a) Sequence plate (b) foil film (c) racks for sequencing (d) small coolers (ice racks). 
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3.8 Second method for SNP genotyping 
 
   SNP genotyping 
 
        1st PCR 
 
                                    Ethanol purification 
 
                               Template generation (2nd PCR) 
 
 Enzyme purification 
 
OLE test for optimization 
 
         OLE assay 
 
Figure 3.5: Sketch for SNP genotyping by OLE assay 
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3.8.1 Primers for OLE assay 
 Primers (forward and reverse) for OLE assay were designed in which 3’ end of 
the each primer was directly adjacent to the nucleotide bases to be identified (Table 3.3). 
Table 3.3 Oligonucleotide primers for one label extension method 
SNP 
no 
Forward primers  Primer 
length 
(bp)  
Reverse primers Primer 
length  
(bp) 
S1 acatcaaatgcattctatagc 21 agagtgactggaacatcctg 20 
S2 acaaaagatgtcctgtttggaac 23 tgaagtaactgatacagagtt 21 
S3 ttccttagaaatgttattgtagt 23 caggattcaggccatcttgcaaa 23 
S4 tactcctgttcggatcccttc 21 tgaagtaactgatacagagttgg 23 
S5 caagtcagggtgtggtcattc 21 ttctgcatcgctgcttacc 19 
S6 cagggtgtggtcattccggta 21 gtcttgattctgcatcgctgc 21 
S7 aaccatatgatcaacagtt 19 tctgcgagtggctgctttt 19 
S8 ggatggggaaggtttttgacttta 24 cccaaaatttgttctgagaatatc 24 
S9 atgcagaatcaagacagagt 20 gagagagaaagaaac 15 
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Table 3.3 continue 
S10 Aggccagacagggctgtg 18 gaccacaccctgacttg 17 
S11 tctattttttaaaaaact 18 aaaacaagagaaaagt 16 
S12  cctttccgtgcctgggtggcc 21 ccctctccacagcgtttt 18 
S13 atcagcacactttgaacatta 21 ccagttggagtgagctgggcc 21 
S14 cccaggaactggagcgaaagt 21 ttttcctcatggggcaaatct 21 
S15 atctgctgccacataaaaccac 22 tataaaggctcagggaatgc 20 
S16 gaaataggagcaggatc 17 attctctgtatatctggaagt 21 
S17 tgggagcagtgtcatggacat 21 aagcctgtccctctgcc 17 
S18 gttctattctgatgccatta 20 tcaactaaaaacagggcaact 21 
S19 gggcccagggtcaatggggta 21 acattacactatcaacatctt 21 
S20 caatcaacctcttccttaag 20 taagacttccttaacatttt 20 
S21 tcaacattctcttagcttctt 21 ccaattttggaaagagat 18 
S22 acttagactactacctcgatg 21 acaattaaataagtcaataata 22 
bp; base pair 
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3.8.2 PCR reaction for OLE template generation 
 After 1st PCR and ethanol purification (same protocol mentioned above) next step 
was template generation which was same as nested PCR with minor change in 
concentrations.  Following reaction mixture was used: 
3.8.2.1 Template generation (2nd PCR), Reaction mixture 
 Forward primer                       0.75 µl 
 Reverse Primer                        0.75 µl 
 Master mix                              10.0 µl  
 H2O (Millipore)                       36.25 µl  
 Taq polymerase                      0.75 µl  
 DNA template                         1.5 µl 
  
                             Total volume                        50 µl 
 
 Above reaction mixture was used for one reaction (one genotype or one base pair 
possibility) in one PCR tube. For each SNP we make three PCR tubes according to three 
genotypes (base pair possibilities of sequence result) and used three DNA templates from 
purified 1st PCR product then labeled them as homozygous dominant, homozygous 
recessive and heterozygous for each SNP. Run PCR program as mentioned above for 
nested PCR. 
3.8.3 Enzyme purification 
 PCR products were treated with Exo nuclease I (ExoI) and Shrimp Alkaline 
Phosphtase (SAP). After template generation (2nd PCR) enzyme purification was done. 
Following reaction mixture was used for enzyme purification. 
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Mixture I 
 SAP buffer (10X)                                               10 µl 
 H2O (Millipore USA)                                          38 µl 
Mixture II 
 EXO 1(5U/ µl)                                                    0.3 µl 
 SAP (Shrimp Alkaline Phosphatase: 1U/µl)      2 .25 µl 
 
Total volume                                                       50.55 µl 
 
 The reaction mixture was transferred to each nested PCR tube. Now total volume 
of each tube was 100 µl. The above mixture was vortex and short spin for several sec. 
Run following program named as 3785 in PCR machine (Applied Biosystem thermal 
cycler model# 9902, Singapore) consisted of initial temperature at 37ᵒC for 45 min 
followed by one cycle of 15 min at 85ᵒC. 
3.8.4 OLE test 
 After enzyme purification, for every SNP appropriate OLE test (optimization) 
was performed in PCR tubes to choose best method for OLE assay i.e., following 
procedure was used for genetic variant rs6511720 (Table 3.4).  
Reaction mixture for OLE test 
 Therminator buffer (TE buffer) (10X )                       2.0 µl 
 Taq pol                                                                          0.3 µl 
 R110-labeled dideoxy-terminators (10 µM)               1.0 µl 
 Primer F/P (5 µM)                                                       1.0 µl 
 H2O (Millipore USA)                                                   up to  20 µl 
 DNA template                                                               1.5 µl 
             Total volume                                                               20 µl 
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3.8.4.1 SNP Rs6511720 (NCBI sequence) 
ATCAACCTCTTCCTTAAGA[G/T]AAAATGTTAAGGAAGTC 
For this genetic variant (rs6511720) following four methods were used for OLE 
assay (according to presence of bases G or T for current sequence) (Table 3.4). 
 
Table 3.4: Different methods used for OLE assay 
Methods Labeled nucleotides 
OLE one base F dGTP*, d UTP* 
OLE one base R dCTP*, d ATP* 
OLE two base F dGTP +, d ATP*/ dTTP, d ATP* 
OLE two base R dCTP + d UTP*/ dATP, dUTP* 
Here *=  represent florescent dye, F = forward primer, R = reverse primer 
 
All work was run in dark. After vortex and short spin all these PCR tubes were 
transferred in to PCR machine and run OLE reaction by use of the following program: 
 
 Denaturation           95ᵒC            5min 
 Denaturation           95ᵒC            30 sec         30 cycles 
 Elongation              55ᵒC            30 sec 
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The above reaction mixture was prepared in appropriate PCR tube. We used four 
PCR tubes for each OLE reaction was done according to schematic diagram 3.6. 
 
Figure 3.6: Sketch of PCR tubes with reaction mixtures for OLE test, = PCR tube, * = dye, F = 
forward primer, R =  reverse primer, (AA, GG, AG) = template DNA with known 
genotypes 
 
 After OLE reaction the PCR tubes were taken out and 10µl product from PCR 
tubes was transferred into each well of black OLE plate of 384 wells (Figure 3.7). The 
plate was sealed and short spin. Florescence polarization (FP) was measured by using 
Wallac VICTOR2V 1420 Multi label Counter (PerkinElmer, Boston, USA) (Figure 3.8) 
(Annexure V).  
 
Figure 3.7: OLE plate 
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Figure 3.8: Multilabel counter 
3.8.5 OLE assay for SNP genotyping 
 OLE reaction (Yu et al., 2006) was carried out in 384-well plates in a 20 μL 
reaction mixture containing (a) 60 ng PCR-amplified DNA template, (b) 0.3 U Taq 
polymerase (TaKaRa Dalia, China), (c) 250 nM OLE primers (5µM) (OLE primers are 
listed in Table 3.3), (d) 4 μL 5× OLE reagents (Pharmaco Genetics Ltd., Hong Kong) 
according to manufacturer's protocol.  
(e) 50nM TAMARA-dNTP (N for A/C/G/U), full names are following 
 Aminoaallyl-dUTP-5/6-TAMARA(TAMARA-dUTP) 
 7-propargylamino-7-deza-dATP-5/6-TAMARA (TAMARA-dATP)  
 5-Propargylamino-dCTP-5/6-TAMARA (TAMARA-dCTP) 
 7-propargylamino-7-deaza-dGTP-5/6-TAMARA(TAMARA-dGTP)  
Jena Biosciences,Germany. 
 After initial denaturation at 95°C for 3 min, primer extension was carried out by 
30 thermal cycles consisting each of 95°C for 30 sec and 55°C for 30 sec. The FP value 
of the OLE reaction was read from the 384-well plate by using the same Wallac 
VICTOR2V as described above (PerkinElmer, Boston, USA) without any purification 
(Annexure VI). OLE assay is summarized in Figure 3.9. 
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OLE assay (two base forward) 
 
5´         CTCACCAATCAACCTCTTCCTTAAGA[G/T]AAAATG         3´ 
3´          GAGTGGTTAGTTGGAGAAGGAATTCT[C/A]TTTAC          5´ 
                                                                                                                                    SNP C/A 
                                                                             OLE primer  
                                                        5 ´ CTCACCAATCAACCTCTTCCTTAAGA  3´ 
                                                                              OLE primer 
                                                        5´ CTCACCAATCAACCTCTTCCTTAAGA  3´ 
                                           3´              GAGTGGTTAGTTGGAGAAGGAATTCT[C/A]TTTAC               5´ 
 
 
               Two separate reactions 
 
 
                                              dTTP     I                                                          II    d TTP 
     R110-ddGTP                                                                       R110-ddTTP 
                                  OLE primer        R110                                    OLE primer       R110 
            GA                                                           TA 
                                                       CT                                                           AT 
 
 
  FP detection                                               FP detection 
                         
 
Figure 3.9:  Schematic presentation of OLE two base extensions 
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3.9 Statistical analysis 
Demographic data (Age, gender, marital status, BMI, education, income, cost, 
family history and smoking) was calculated by the use of R version 2.11 software for all 
patients enrolled in the study. Wilcoxon signed-rank test for continues values (BMI, age) 
and Chi-square test for discrete values (gender, marital status, family history, smoking, 
history of diabetes, hypertension and hyperlipidemia) was used. Continuous values were 
presented as mean ± standard deviation (SD) and categorical values were exhibited in 
numbers as well as percentages. Association studies for the relationship between one 
continuous variable (BMI, cost) and other independent variables (family history, rural 
and urban population and income) were carried out by 'Kruskal Wallis' and 'Mann 
Whitney U' test. The box and whisker plots were created for association between 
different income groups of patients and for comparison of BMI with family history and 
urban and rural population respectively by using R version 2.11. The P value less than 
0.05 was considered as statistically significant.  
3.9.1 Hardy-Weinberg Equilibrium 
 Exact test of Hardy-Weinberg Equilibrium (HWE) was performed by the program 
GENEPOP version 3.4 (Raymond and Rousset, 1995) for control samples, with the 
following parameters: dememorization number (1000), number of batches (100) and 
number of iterations per batch (1000). The Hardy–Weinberg principle states that in a 
population both allele and genotype frequencies remain constant generation after 
generation with the absence of external disturbing influences. For a single locus with two 
alleles: the frequency of major allele (A) and minor allele (a) are denoted as p and q; 
frequency (A) = p; frequency (a) = q; p + q = 1. If the population is in equilibrium, we 
will have frequency (AA) = p2 for the AA homozygote in the population, frequency (aa) 
= q2 for the aa homozygote, frequency (Aa) = 2pq for the heterozygote, and p2 + 2pq + q2 
= 1. If the observed allele and genotype frequencies in a population are significantly 
deviated from this equilibrium, probably non-random mating, mutations and selection are 
present in the population or the sample size of the population is too small. For this reason, 
all the control groups for the disease association analysis should pass this HWE test. 
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3.9.2 Genetic association 
 The disease association analysis was carried out by using software package 
UNPHASED version 2.404. Additional soft ware SHEsis, Chi sq 2/2 were employed in 
order to compare allele and genotype frequency of cases and control for all SNPs. if any 
allele (or genotype) have higher frequency in cases than control; then we called it is 
associated in causing disease. Permutation procedures of 100 replicates were employed to 
obtain empirical P values by means of UNPHASED program. To evaluate the association 
between APOA5 and plasma triglyceride levels, a multiple logistic regression model was 
fitted. Demographic parameters were analyzed for second phase of study (comparison 
between cases and control) by using SPSS v 18.0 package. 
3.9.3 Linkage disequilibrium 
 Two common parameters of LD: D′ and r2 were calculated by SHEsis for SNPs in 
the same gene. D′ is scaled from 0 to 1 by the observed marker allele frequencies such 
that a D′ of zero indicates no LD and a D′ of 1 indicates the maximum possible LD given 
those allele frequencies. Another measure, r2 is a squared correlation coefficient and 
denotes the ability of alleles at one locus to predict alleles at the second locus on similar 
choromosomes. 
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CHAPTER 4 
RESULTS 
 
4.1 Demographic distribution of MI (First phase) 
 The data collected from North of Punjab Pakistan indicated out of 515 patients 
from rural and urban areas, 356 (69.13%) were males as compared to females 159 
(30.87%) in this phase of study. The mean age of participants of rural areas was 56.8 
years and of urban areas was 55.7 years with a range of 20-80 years. The MI was 
significantly higher among males as compared to females in both urban and rural 
population (P = 0.015) (Figure 4.1). According to age MI patients were divided in to 
three groups. Groups I consisted of 20- 40 years of age and contain 12.23% of MI 
patients. Groups II comprises 41-60 years of age have 53.79% patients and group III have 
patients ≥ 61 years with 33.98% patients.  In case of BMI, obesity (BMI ˃ 25) was found 
among 43.11 % participants with MI. In addition 72.04 % patients were found with 
previous family history of heart attack. There was a low literacy rate among MI patients. 
The 39.03% patients were found illiterate and 41.36% patients were without any job 
(Table 4.1).  
4.1.1 CO-morbid conditions and family history related to MI 
The patients with ST Segment Elevation Myocardial Infarction (STEMI) were 56% more 
as compared to Non Segment Elevation Myocardial Infarction (NSTEMI) 44% (P > 0.05).
 Smoking was more common (32.8%) in MI patients of rural areas as compared to urban 
areas (28.1%). However, there was no significant difference of smoking (P = 0.20) 
between rural and urban areas. Overall 60.9% patients were smokers. The 70% patients 
were having sedentary life. There was high prevalence of hypertension (37%) as 
compared to diabetes (19.4%) in MI patients of Pakistani population (Table 4.2). The 
26% of selected MI cases had hyperlipidemia (cholesterol level ≥ 200 mg/dl) while 17% 
patients had two or more risk factors (Table 4.2).  
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Table 4.1 Demographic distribution of myocardial infarction 
Parameters Rural (%) Urban (%) Total (%) 
Subjects 265 (51.46) 250 (48.54) 515(100) 
Gender 
Male 
Female 
 
170 (33.0) 
95 (18.4) 
 
186 (36.1) 
64 (12.4) 
 
356 (69.13)* 
159 (30.87) 
Age 
20-40 
41-60 
≥ 61 
 
38 (7.38) 
136 (26.41) 
91 (17.67) 
 
25 (4.85) 
141 (27.38) 
84 (16.31) 
 
63 (12.23) 
277 (53.79) 
175 (33.98) 
BMI 
≤ 25 
>25 
 
205 (39.81) 
60 (11.65) 
 
88 (17.09) 
162 (31.46) 
 
293 (56.89)* 
222 (43.11) 
Family History 
+ve family history 
-ve family history 
 
 
235 (45.63) 
30 (5.83) 
 
 
136 (26.41) 
114 (22.14) 
 
 
371 (72.04)* 
144 (27.96) 
Education 
Illiterate 
Primary 
College & above 
 
99 (19.22) 
77 14.95) 
89 (17.28) 
 
102 (19.8) 
59 (11.46) 
89 (17.28) 
 
201 (39.03) 
136 (26.41) 
178 (34.56) 
Marital. Status 
Married 
Unmarried 
 
251 (48.74) 
14 (2.72) 
 
240 (40.60) 
10 (1.94) 
 
491 (95.34)* 
24 (4.66) 
Employment status 
Jobless 
Laborer 
Housewifes 
Office job/business 
 
144 (27.96) 
8 (1.55) 
12 (2.33) 
101 (19.61) 
 
69 (13.40) 
76 (14.76) 
27 (5.24) 
78 15.14) 
 
213 (41.36) 
84 (16.31) 
39 (7.57) 
179 (34.76) 
Results are presented in numbers of patients (percentage). Rural = Rural population (Faisalabad, 
Gujranwala, Gujrat and Sialkot), Urban = Urban population (Lahore, Islamabad), BMI (Body mass index) 
was considered as being normal at ≤ 25 and overweight at > 25 for both men and women according to 
WHO: Bold letters are representing the higher percentage among groups. (* = P < 0.05) 
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Table 4.2 Co-morbid conditions and types of myocardial infarction  
Parameters Rural (%) Urban (%) Total (%)          Chi-sq P values 
No. of patients  265(51.4) 250(48.5) 515 (100)  
Types     
STEMI 152(30) 138(27) 290(56)                   0.65 
NSTEMI 113(22) 112(22) 225 (44)             
Smoking     
Smokers 169(32.8) 145(28.1) 314 (60.9) 0.20 
Non smokers 96(18.6) 105(20.3) 201 (39) 
Life style     
Sedentary 151(29) 213(41) 364(70) 0.00* 
Physical activity 114(22) 37(7) 151 (29)             
Other 
Complications 
   
 
Hypertension 90(17) 100(19.4) 190 (37) 0.00* 
Diabetes 35(7) 65(13) 100(19.4)  
Hyperlipidemia 100(19.4) 35(7) 135 (26) 
Risk Factors≥ 2 40(8) 50(8) 90 (17) 
Results are presented in numbers of patients (percentage) * = P < 0.05 
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Figure 4.1: Prevalence of myocardial infarction in Urban and rural areas of Pakistan.  
 
 
The BMI and family history of MI patients was compared. In comparison of this  
it was found participants with 1st degree relative positive family history experienced MI 
even at BMI ≤ 25 kg/m2 (Figure 4.2). In the next step BMI was compared among urban 
and rural MI patients, it was noticed patients of urban population were significantly more 
overweight as compared to rural patients (P < 0.05) (Figure 4.3).  
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Figure 4.2: Box and whisker plots for Comparison of BMI (Kg/m2) with family history. The 
boxes represent a 25–75% range of the values and the whiskers represent the 
minimum and maximum values. The median values are marked with a dark line in 
the boxes. Excluding outliers are shown with circles. 
 
 
 
 
 
 
Figure 4.3: Box and whisker plots for comparison of BMI (Kg/m2) with rural and urban 
population (P = 0.0041). Key as for Figure 4.2 
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4.1.2 Economic burden 
Relationship between monthly income and overall cost (ECG, CT scan, 
Angiography, surgery and medication) of MI patients was presented in Figure 4.4. All 
income classes (lower, middle and higher) were spending almost equal amount for the 
treatment of disease. The mean cost of monthly medicine and physicians after three 
months check-up was 2381.132 PKRs (24.24 USD) with annual cost was 9524.53 PKRs 
(96.96 USD).The mean cost for heart surgery was 600 thousand (6108.19 US$). 
 
Figure 4.4: Box and whisker plots for comparison between surgery cost and monthly income of 
MI patients (K= 1000 PKRs). Key as for Figure 4.2 {mean cost for surgery = 600 
thousand (6108.19 US$) 
 
4.2 Second phase (Genetics study)  
In the second phase, total of 384 subjects (192 each of MI and control) were 
genotyped (sequencing and OLE assay) for all 22 SNPs selected for current study. Out of 
22 SNPs only 3 did not show two base pair possibilities (homozygous dominant and 
recessive) in selected population. Therefore, these three SNPs rs6511720 (S20), 
rs1537375 (S21) and rs4986790 (S22) were excluded from any disease association 
analysis. Selected individuals were in the age group from 20-80 years with mean age of 
cases and control was 55.6 and 53.4 years respectively. 
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4.3 Clinical characteristics 
The clinical characteristics for second phase of study among cases and control 
subjects are listed in Table 4.3. The cases had significantly higher (P < 0.05) cholesterol, 
LDL-C, triglycerides, BMI, smoking, hypertension and diabetes as compared to control. 
Detail of optimized primers for annealing temperature and sequenced primers used are 
summarized in Table 4.4. 
 
Table 4.3  Basic characteristics of MI and normal controls in Pakistani 
population 
Variables Case (n=192) Control (n=192) Total(n=384) 
Age (year) 55.6±0.8 53.44±0.8 54.45±0.6 
Gender 
    
Male 145 130 275 
Female 47 62 109 
BMI (KG/m2) 28.4±1.1* 22.6±0.2 25.5±0.6 
Smoking (%) 50.2* 19.4 19.4 
Hypertension (%)  54.5* 25.2 25.2 
Diabetes (%) 30.6* 10.1 10.1 
Triglycerides 
(mg/dl) 
195±2.8* 124±1.7 159±2.4 
LDL-C(mg/dl) 155±1.9* 111±2.9 133±2.0 
HDL-C (mg/dl) 42±1.0 50±0.8 46.3±0.6 
All continuous variables are expressed in means ± standard error (SE) and categorical variables 
are expressed in number with percentage in parentheses. Abbreviation: LDL-C = low density 
lipoprotein cholesterol, BMI = body mass index, HDL-C =  high density lipoprotein cholesterol, 
*P < 0.05 
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Table 4.4 Annealing temperature and sequencing primers used for sequencing of 
selected SNPs 
SNP 
NO 
SNP ID Chr Gene 
 
Annealing 
TM 
(°C) 
Sequencing 
primer 
S1 rs4977574 9p21.3 CDKN2A/B 
 
56 R 
S2 rs2891168 9p21.3 CDKN2A/B 
 
58 F 
S3 rs2383206 9p21.3 CDKN2A/B 
 
60 F 
S4 rs2383207 9p21.3 CDKN2A/B 
 
56 F 
S5 rs10811656 9p21.3 CDKN2A/B 
 
56 F 
S6 rs10757278 9p21.3 CDKN2A/B 
 
58 F 
 
S7 rs1333049 9p21.3 CDKN2A/B 
 
58 F 
 
S8 rs10757283 9p21.3 CDKN2A/B 
 
56 R 
 
S9 rs1333047 9p21.3 CDKN2A/B 
 
56 F 
 
S10 rs10757277 9p21.3 CDKN2A/B 
 
60 F 
 
S11 rs10757279 9p21.3 CDKN2A/B 
 
56 F 
 
S12 rs3135506 11 APOA5 
 
58 F 
 
S13 rs1558861 11 APOA5 
 
58 F 
 
S14 rs662799 11 APOA5 
 
60 R 
 
S15 rs10750097 11 APOA5 
 
58 F 
 
S16 rs599839 1P13.3 PSRC1 
 
60 F 
 
S17 rs646776 1P13 CELSR2 56 R 
 
S18 rs3846663 5q13.3 HMGCR 56 F 
S19 rs2271293 16 NUTF2 56 F 
S20 rs6511720 19 LDLR 60 F 
S21 rs1537375 9 ANRIL 58 F 
S22 rs4986790 9 TLR4 58 F 
Chr =  chromosome; TM = temperature; F = forward; R = reverse 
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4.4 Genomic DNA extraction from human blood 
The concentration of genomic DNA which was extracted from blood was at least, 
80 µg/ ml measured by nanodrop and also was imaged by 1.0% agarose gel. Extracted 
DNA samples were shown in Figure 4.5.      
         
Genomic DNA of different samples in 1% agarose gel
 
Figure 4.5: Genomic DNA extracted by whole blood 
 
 
 
A total of 9 genes were carefully selected for analysis selected from extracted 
DNA based on the reported genetic association with MI from NCBI database, 22 SNPs 
were identified and evaluated for the association with MI. As an example one gene 
indicating the region of SNP location with first and nested PCR primers are as follows 
(Figure 4.6). 
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db SNP: rs10757278 
Find in NCBI database (Fasta)  
 
AATAAATATTGTATTAGTTCTCATTTTGTAAAACTTATACAGGTATCATATGCATAGAC
AAATACACCAAACTGATGAATATTTGCCTTGTATAATCTTTTTGTAGTTTTTTTATGAACATATA
TTACTCAAACAATTTAGAACATTTGGCAATATATATATATTTCATTTATAAAAGGTTAGGAAGAT
TAATTACACTTTCTGAGGTCGCAACTAAAAGCCAAGATTTTAATCCATTTCTATTTGATGTAAAG
TCTGGTCTTTTTTCAGCAAACCACAATCCCACATTTTAAGGGCATTAAGAAAGGGATGGGTAGAC
AAAATGTAGAGGTAGTAGGTACAGAATACAAAGTTTCAAGAAATTAAAAGCTTCTAAACTAACAA
ACAGCCAATTTGTGGAGTGTCACTGGAAAGTGACAAAGAGGACAGTTAAGTTAGTTGGAACTGAA
CTGAGGCCAGACAGGGCTGTGGGACAAGTCAGGGTGTGGTCATTCCGGTARGCAGCGATGCAGAA
TCAAGACAGAGTAGTTTCTCCTTCTCTCTCTCTCTTTAATTGTAACGCCTTTTATAACAAACAAA
TATTATGCTTATTTCTGTCTTTAAATTTTTTGTAGTAATTTCTCATCACTTAACCTCTATTTTTT
AAAAAACTAACTTTTCTCTTGTTTTTCTAGTTGAGCTATCATTCATATTTATTATGTGGAACTAG
AGGTAGTCCTGGCTACTTGGGAACAGCGTGGAGTCTAGCCATGTCAGGGCCAGAAGTCGTCTCAG
CTAAGTTAGAATGTGATACCATTGTTTACACAAGTGTGGCCTGCCTTCAAGATAGGGTGAGGTGT
TTTATGACCACAGGCTTTATGAGTTATAGCTATAAAACAATCAATCTTTTAAAGCAAACACACCA
CAATGTCTACACGCAAATGAGAATTGTCCTTCAGGGCTGTGACCTTGGGAAACTCTTCACACATA
CTAGCATAAAACATATTTAAACTCTTCACTG 
 
FIND IN UCSC (dB SNP: rs10757278) 
 
TTTCCTACTCTTTAATTAGATTGTTTTTACTGTTGAGATGTTTGAGTCCCTTATATATT
CTAGATATTAATCTCTTGTCAGATGAGTAGTTTGCAAATATTTTCTTCCATTCTGTAGTTTGTAT
ATTCACTCTGTTGATTACTTCCTTTGCTGTACAAAAGCTATTTGGATTGATATAATCCCATTTGT
GTATTTTGTTTGTGTTACCTATGTTTTTAAGGTATTATTCAGAAAATTTTTGCCCAGACCAAGGT
CCTGAAGCATTTCTTCTATGTTTTCTTCTAGTAATTCTATTTTTCATGTCTTACATTTAGGTTTT
TGATCCATTTTGCAATGATATTTATATAGGGTGAGAGACGGGAATCTAGTTTAATTCTTCTGCAT
ATAGATATCCAGTTTTCCCAGCACCATTCGTTGAGGAGACTGTCCTTTACCCACTGAGTGTTCTT
GATATCTTTGTTAAAAATCAGGTGGTTGTAGATATGTGGATTAATTTCTGGGTTCTCTATTCTGT
TCTATTGATCTATGTGTCTGTTTTTATACCAGTACCATGCTATTTTGTTTACTATAGCTTTGTAG
TATACTTTGATGTCTGGTAGTGTGATAACTCCAGCTTTGTTCTTTTTGCTTAGGATTGCTTTGGC
TGTTTGGGGTCTTTTGTGGTTCCATATAAATTTTAGAATTTTTTTTTCTATTTCTGTGAAGAACG
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TCATTAGTATTTTGATAGGGATTGCATTGAATCTATAGGTTGCTTTGGGCAGCAGATATCTTTCC
ATTTGTTTATGTCCTTTTCCATTTCTTTCATCAGTATTTTGTAGTTTTAGTTGCAGAGGTCTTTC
ACCTCCTTGGTTACATTTATTCCTTGGTATTTTATTGTTTTCGTAGCTATTGTAAATGGGATTGC
CTTCTTGATTGCTTTTTCAGCTAGTTCATTGTTCATGTATAGAAATACTACTGATTTTTGTATAT
TGATATCGTATTCTGCAACTTTACAGAATTTGTTATTAGCTCTGAGTTTTTTGGTAGAGTCATTA
GATTTTTCTGTATATAAAATCATGTCATCTGCAAACAGGAACAATTTGACTTCCTCCTTTCCAAT
TTGGATGTCCTTTATTTCTTTGTCTTGCCTAGTTGCTTGGGCTAGGACTTCCATTACTGTGTTGA
ATAAGAATGTTAAGAGTGGGCATCCTTGTCTTGTTTCAGTTCTTAGAGGAAATGCTAGTGTAGCT
GAGGAGAGAAATGAAAACAGAATAAAAACTTCAGTAGAAGTTGGGGAGAAATGTGTTTGCACCAA
AAGAGGTGAGGGATGGAACTGAGGGAGGTCTCGAGGGGTAAGAGAGGCCAAAGAGCTGGCAGGTG
CTGCTATTAGGATGGCCAATGATCCAGAAGTAATGATGAATGAGAAGATGGATTAAAAAAACCCT
GACATTGTTTAACTAGAAGAAGAAGACAGTCAGAGAGAAGTGAGGGCTTACTTTTCATGTTTAAA
GTCTGTTATGTGGTAAAGGGATTAGATTTATCTGTGTTGTTCCAGGGGACAGAAATAGGACAAAT
GGATGCAAATAGAGTGAGGAAGATTTAAAACAAATGGAGAAGACATTCTAAAATCAACTACAATG
AGCGTAAACAATGACAACGGAAAGGACTATTTTTGCAATTATGTAGCTCTTGTTCTCTATAGATA
GATGTGTAAGCAGACGCTGAATAACCATTTACTGAAAATATAAATAAAAACAAAGCAAATTGCAG
GCAATAAATATTGTATTAGTTCTCATTTTGTAAAACTTATACAGGTATCATATGCATAGACAAAT
ACACCAAACTGATGAATATTTGCCTTGTATAATCTTTTTGTAGTTTTTTTATGAACATATATTAC
TCAAACAATTTAGAACATTTGGCAATATATATATATTTCATTTATAAAAGGTTAGGAAGATTAAT
TACACTTTCTGAGGTCGCAACTAAAAGCCAAGATTTTAATCCATTTCTATTTGATGTAAAGTCTG
GTCTTTTTTCAGCAAACCACAATCCCACATTTTAAGGGCATTAAGAAAGGGATGGGTAGACAAAA
TGTAGAGGTAGTAGGTACAGAATACAAAGTTTCAAGAAATTAAAAGCTTCTAAACTAACAAACAG
CCAATTTGTGGAGTGTCACTGGAAAGTGACAAAGAGGACAGTTAAGTTAGTTGGAACTGAACTGA
GGCCAGACAGGGCTGTGGGACAAGTCAGGGTGTGGTCATTCCGGTAAGCAGCGATGCAGAATCAA
GACAGAGTAGTTTCTCCTTCTCTCTCTCTCTTTAATTGTAACGCCTTTTATAACAAACAAATATT
ATGCTTATTTCTGTCTTTAAATTTTTTGTAGTAATTTCTCATCACTTAACCTCTATTTTTTAAAA
AACTAACTTTTCTCTTGTTTTTCTAGTTGAGCTATCATTCATATTTATTATGTGGAACTAGAGGT
AGTCCTGGCTACTTGGGAACAGCGTGGAGTCTAGCCATGTCAGGGCCAGAAGTCGTCTCAGCTAA
GTTAGAATGTGATACCATTGTTTACACAAGTGTGGCCTGCCTTCAAGATAGGGTGAGGTGTTTTA
TGACCACAGGCTTTATGAGTTATAGCTATAAAACAATCAATCTTTTAAAGCAAACACACCACAAT
GTCTACACGCAAATGAGAATTGTCCTTCAGGGCTGTGACCTTGGGAAACTCTTCACACATACTAG
CATAAAACATATTTAAACTCTTCACTGAAAATATTATTCAGACCTAGTTTCTCTCTCAGTCTCTC
TCTATGTTTCTCTCTCACATGTACGTGCATGCACGCACACGTGTGCACACACACATATGCTCACA
TCATTTTAAGATACATCTCATTTTTAACCAAAACCATTTTATCTTGCTTGATAACCAATTTTATT
67 
 
TGTTAGATGACTTGGCTATAAATGCCTTTGGCTATCAGGAAAATCAAATCAAAATTAAAAGACAC
TGTTACTACTGAAGAAGTAAAAAAAGAATGGGCTGCTGACTCTGAAGATCATACCCGAAGTAGAG 
CTGCAAAGATATTTGGAATATTGGTAATATCCAATAAAGAATGACCTTCATGCTATTTTGAGGAG
ATGTTTAAATGTCGAATTATTGAAATATTTATAAAATACAAATAAACTAACTCTGCTTCATATTC
CAACTTGTGTATGACACTTCTTAGGCTATCATTTCATTCCAAATTTATGGTCACTACCCTACTGT
CATTCCTCATACTAACCATATGATCAACAGTTGAAAAGCAGCCACTCGCAGAGGTAAGCAAGATA
TATGGTAAATACTGTGTTGACAAAAGTATGCAGAAGCAGTCACATTTATACAGTAGTGAAGGAAA
TGTAAATTGGACAAACTTTTTGGAAGATAAGTTGAGAATGTCAAAAATCAAAACACACTTTCTGT
TTTATTCAGCAATTATGAGCCCTTTGTTTTACAGCTATGCTCACAAATATATACAAACATGTATG
CACAATTATGTTCACTGTGGTATTGCGCTAGAAAAATACTAAAAACAAACCAAATGTTCATCAAT
AGGGAAATTGTTCAACAAATTACAGTATATCTAAAAAAAGAATAATATATAACAACTGAAAAAAT
AAAATAGTTGATATAAGCAGATATTCCAAGATCTGCCAGACATATTGTTAAACGAAAAATCTAGA
TACAAAATTGTTTATAGTTCTCTTTCATACTATAGCCAAAGAAAATTCAGAAAAAACTACTTACA
GTTGATCCTTGAATAATGCAGCAGGTAGGGGCACCAGCTTCCTGCGCAGTCAAGAATTGCATATA
ACTTTTGACTCCCCCAAAACTTTGCTAATAGCCTACTGTTGACTGGAAGCCTTATCAACAACATC
AACAGTTGATTAACACTGGAAAAGGAGGGGTTGGTCTTACTGTCTCAAGGGTGGCAAAGGCGGAA
GAAAAGCCACCTATAAGTGAACCCTTGAAGTTCCAACCTATGTTTTTCCAGGGCAATCATACATC
CATGTCCATATTCATGATGAATATGTGAAAGGGTACATAAGAAAATGTGATAGTCGTTTCCTCTG
GAGAATAAAATGAGAGGTCTATCATAGGTGAGAAAATAATTTTTTATTATATATTCTTTTGTAGG
TTTATTTTTTTGTCATGTGTATGTATTCTTTTCAAAATAATAAAAACAATAACAACGATTAAAAT
ATACAAGGGGAAATGCATTGGCCAAGGTTTAGTTGAGAGCAAAGTTTGCTTATCTTTCGAAAGAG
GTGAACTAAGCTTTTCCTTTTTCTCTTTGGGTATACTTGAATGGGGATGGAGTAAGTGGATTCTT
TTTTTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCGCCCAGGCCGACTGCAGTGGCGCTATCTC
GGCTCACTGCAAACTCCGCCTCCGGAGTTCACGCCATTCTCCTGCCTCAGCCTCCCGAGTAGCTG
GGACTACAGGCGCCCGCCACTG 
 
 
Figure 4.6: Part of data base sequence of gene CDKN2A/2B (rs10757278). Yellow color 
represents the 1st PCR product while the ferozy color represents the nested PCR 
product. While red colour in NCBI and UCSC sequence representing SNP location 
for gene CDKN2A/2B (rs10757278) 
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4.5 Nested PCR product 
After the extraction of genomic DNA, all samples were amplified by nested PCR. 
The PCR products were imaged by 1.0% agarose gell electrophoresis. Results of nested 
PCR products for 11 genes are shown in Figure 4.7 (a-i) with 1kb DNA marker.  
                   1 kb ladder                             Nested PCR fragments 
 
 
Figure 4.7 (a): Nested PCR product for gene CDKN2A/2B (rs10811656) with 
product size = 559 visualized in 1% agarose gel                     
 
                   1 kb ladder                       Nested  PCR fragments 
  
 
Figure 4.7 (b): Gene APOA5 (rs3135506) product size = 650 
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                          1 kb ladder                    Nested  PCR fragments 
 
 
 
Figure 4.7 (c): Gene PSRC1 (rs599839) product size = 539 
 
 
        1 kb ladder                            Nested  PCR fragments 
 
 
 
Figure 4.7 (d): Gene CELSR2 (rs646776) product size = 560 
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   1 kb ladder                                     Nested PCR fragments 
 
 
Figure 4.7 (e): Gene HMGCR (rs3846663) with product size 698 bp 
 
 
                1 kb ladder                        Nested PCR fragments 
 
 
       
Figure 4.7 (f): NUTF2 (rs2271293) with product size 529 bp 
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               1Kb ladder                        Nested PCR fragments 
 
 
Figure 4.7 (g): LDLR (rs6511720) with product size 669bp 
 
 
  
                           1Kb ladder                   Nested PCR fragments  
 
Figure 4.7 (h): ANRIL (rs1537375) with product size 750 bp 
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1 kbLadder                        Nested PCR products 
 
 
 
                               (i) Gene LDLR (rs6511720) with product size 669 bp 
 
 
                 1 kb ladder                      Nested PCR fragments   
 
(j) Gene TLR4 (rs4986790) with product size 690 bp 
Figure 4.7 (a-j): Nested PCR products visualized in 1% agarose gel 
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4.6 Recognition of SNP site 
 Chromatograms (Figure 4.8) are showing the SNP sites within the part of 
nucleotide sequence. These chromatograms are representing three genotypes; 
homozygous dominant, heterozygous and homozygous recessive identifying by arrow in 
DNA sequencing for each database (dbSNP). There were three SNPs (rs6511720, 
rs1537375 and rs4986790) out of 22, having only one genotype (homozygous) in cases 
and control (Figure 4.8 p, q, and r).  
 
 
                          
                                  A                                                                 B 
 
 
           C                                
Figure 4.8 a: Part of nucleotide sequence of rs1048990 SNP (CDKN2A). (A) CC genotype; (B) 
CG genotype; (C) GG genotype 
 
 
74 
 
 
                                   
                               A                                                             B                                                                     C 
Figure 4.8 b: Part of nucleotide sequence of rs4977574 SNP (CDKN2A). (A) CC genotype; (B) CT genotype; (C) TT genotype 
           
      A                                                                                                                       B                                                                      C 
 
Figure 4.8 c: part of nucleotide sequence of rs2891168 SNP (CDKN2A). (A) GG genotype; (B) AG genotype; (C) AA genotype 
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                           A                                                               B                                                                                     C 
Figure 4.8 d: Part of nucleotide sequence of rs10811656 SNP (CDKN2A). (A) CC genotype; (B) CT genotype; (C) TT genotype 
 
                               
                             A                                                                        B                                                                         C 
Figure 4.8 e: Part of nucleotide sequence of rs10757278 SNP (CDKN2A). (A) AA genotype; (B) AG genotype; (C) GG genotype 
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                         A                                                                       B                                                                                     C 
Figure 4.8 f: Part of nucleotide sequence of rs1333049 SNP (CDKN2A). (A) GG genotype; (B) GC  genotype; (C) CC  genotype 
 
                            
                             A                                                                    B                                                                                C 
Figure 4.8 g: Part of nucleotide sequence of rs10757283 SNP (CDKN2A). (A) CC genotype; (B) CT genotype; (C) TT genotype 
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                        A                                                                                        B                                                                                     C 
Figure 4.8 h: Part of nucleotide sequence of rs1333047 SNP (CDKN2A). (A) AA genotype; (B) AT genotype; (C) TT genotype 
 
 
                          
                               A                                                                         B                                                                          C 
Figure 4.8 i: Part of nucleotide sequence of rs10757277 SNP (CDKN2A). (A) AA genotype; (B) AG genotype; (C) GG genotype 
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         A                                                                                        
B                                                                                     C 
Figure 4.8 j: Part of nucleotide sequence of rs10757279 SNP (CDKN2A). (A) AA genotype; (B) AG genotype; (C) GG genotype 
                    
                                    A                                                                   B                                                                  C 
Figure 4.8 k: Part of nucleotide sequence of rs1558861 SNP (CDKN2A). (A) CC genotype; (B) CT genotype; (C) TT genotype 
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                              A                                                                      B                                                                                     C 
Figure 4.8 l: Part of nucleotide sequence of rs662799 SNP (CDKN2A). (A) GG genotype; (B) AG genotype; (C) AA genotype 
                            
                                   A                                                                     B                                                                              C 
Figure 4.8 m: Part of nucleotide sequence of rs4665058 SNP (CDKN2A). (A) AA genotype; (B) AC genotype; (C) CC genotype 
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     A                                                                                        B                                                                                     C 
Figure 4.8 n: Part of nucleotide sequence of rs3846663 SNP (CDKN2A). (A) CC genotype; (B) CT genotype; (C) TT genotype 
                    
                       A                                                                                 B                                                                         C 
Figure 4.8 o: Part of nucleotide sequence of rs3918242 SNP (CDKN2A). (A) TT genotype; (B) CT genotype; (C) CC genotype 
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Figure 4.8 p: Sequence of rs6511720 SNP (LDLR) GG genotype.         Figure 4.8 q: Sequence of rs1537375 SNP (ANRIL) CC genotype 
 
 
 
 
 
.         Figure 4.8 r: Sequence of rs4986790 SNP (TLR4) only AA genotype was found
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4.7 OLE test and OLE assay analysis 
 OLE test results of one SNP (rs10757278) are shown in Annexure V. According 
to FP readings from multilable counter of OLE test (tempelate generation), that method 
(one out of four methods) was selected for OLE assay which depicted higher value of 
homozygous genotype. Results with base line value of OLE assay for one SNP 
rs10757278 are described in Annexure V. 
4.8 Association of candidate genes 
 As described in section 4.2, out of 22 SNPs 19 were selected for disease 
association analysis and were in HWE (HWE exact test P > 0.05) in the control group. 
After HWE test, all 19 genetic variants were included for disease association analysis.  
4.8.1 Allelic associations of 9p21 locus with MI 
 The CDKN2A/B gene (chromosome 9p21.3) was sequenced for 11 SNPs and out 
of them only 8 were strongly associated with onset of MI (P ≤ 0.05). In case of allele 
level significant associations with MI at chromosome 9 were found at following genetic 
variants: rs4977574 (S1) risk allele G with odd ratio 1.394 (1.09,1.90) (P = 0.037), 
rs2891168 (S2) risk allele G (P= 0.016) with OR 1.48 (1.09,2.00),  rs2383206 (S3) risk 
allele G (P = 0.02), rs2383207 (S4) risk allele G (P = 0.0002), rs10811656 (S5) risk 
allele T (P = 0.0012), rs10757278 (S6) risk allele G (P = 0.005), rs1333049 (S7) risk 
allele C (P = 0.02) and rs10757283 (S8) risk allele T (P = 0.01). While three SNPs, 
rs1333047 (S9), rs10757277 (S10) and rs10757279 (S11) of 9p21.3 locus were not 
significantly (P > 0.05) associated with disease (Table 4.5 and 4.6).  
The SNP rs10811656 and rs10757278 from CDKN2A/B (P = 0.006 and 0.004 
respectively) were with three genotypes (CC, CT and TT and AA, AG and GG) and their 
minor alleles TT and GG were found with greater frequency (0.13 and 0.08) in patients 
than control (0.07 and 0.03). The studied SNPs were strongly associated with MI onset 
(Table 4.7). 
 
83 
 
 
4.8.2 Allelic associations of lipid metabolism related SNPs with MI  
 
 Further we analyzed 8 SNPs (chromosomes 1, 5, 11 and 16 respectively) 
previously reported to be associated with LDL-C, HDL-C, triglycerides and CHD from 
GWAS. A significant association of these genetic variants was determined with MI. 
The 4 SNPs (S12, S13, S14 and S15) were located in APOA5 gene, 2 SNPs (S16 and 
S17) were found in CELSR2/SORT1/PSRC1 gene, 1 SNP (S18) in HMGCR gene and 1 
SNP (S19) in NUTF2 gene. Genetic variants of both APOA5 and CELSR2 genes were 
strongly associated with onset of disease.  
 
The minor alleles of APOA5 SNPs rs3135506 (S12; allele C), rs1558861 (S13; 
allele C), rs662799 (S14; allele G) and rs10750097 (S15; allele G) were more 
significant (P < 0.05) among MI group than control. Two SNPs: rs599839 minor allele 
G (P = 0.009) and rs646776 minor allele G (P = 0.001) depicted strong association with 
disease and were located on the same chromosomal region 1p13.3 (PSRC1/ CELSR2). 
Minor allele frequencies of all selected SNPs in MI patients compared with control 
were shown in Table 4.5and 4.6. 
 The gene HMGCR is located on chromosome 5 and one SNP (rs3846663) was 
targeted on this locus. The odd ratio for variant rs3846663 (S18) (Table 4.6) was 1.72 
with 95% CI (1.27-2.32). One SNP rs2271293 (S19) from NUTF2 gene have no any 
impact for risk of MI. Upon comparison of the genotypes of SNPs obtained with OLE 
assay for all 384 samples with those scored by direct DNA sequencing 100% agreement 
was found reconfirms the results for SNP genotyping. Genotype frequency differences 
were also analyzed. Overall significant genotype associations with MI was observed for 
variants; S2, S3, S4, S5, S6, S8, S12, S13, S14, S15, S16 and S17 (Table 4.7). 
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Table 4.5 Disease association of all SNPs by UNPHASE program 
       Minor allele frequency (%)                                                     
SNP 
NO 
SNP ID 
Variation   
M/m 
control (n=192) 
Case 
(n=192) 
P value 
S1 rs4977574 A/G 26 33 0.037* 
S2 rs2891168 A/G 32 41 0.016* 
S3 rs2383206 A/G 26 33 0.022* 
S4 rs2383207 A/G 26 39 0.0002* 
S5 rs10811656 C/T 25 35 0.0012* 
S6 rs10757278 A/G 24 34 0.005* 
S7 rs1333049 G/C 38 46 0.02* 
S8 rs10757283 C/T 27 35 0.01* 
S9 rs1333047 A/T 34 32 0.53 
S10 rs10757277 G/A 35 37 0.4 
S11 rs10757279 G/A 35 34 0.801 
S12 rs3135506 G/C 26 33 0.033* 
S13 rs1558861 T/C 26 34 0.02* 
S14 rs662799 A/G 20 28 0.03* 
S15 rs10750097 A/G 27 41 0.0001* 
S16 rs599839 A/G 47 56 0.009* 
S17 rs646776 A/G 33 44 0.001* 
S18 rs3846663 C/T 32 45 0.0003* 
S19 rs2271293 G/A 30 32 0.8 
M = major allele; m = minor allele, * =  significant (P < 0.05), Adjusted 
P value from permutation test = 0.009901; standard error = 0.009901 
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Table 4.6 Single nucleotide polymorphisms associated with myocardial infarction 
 SNP SNP_ID HWE RR(95% Cl) OR(95% Cl) †P value 
S1 rs4977574 0.26 1.26 (1.01,1.58) 1.394(1.09,1.90) 0.039* 
S2 rs2891168 0.86 1.28(1.06,1.56) 1.48 (1.09,2.00) 0.012* 
S3 rs2383206 0.71 1.29 (1.03,1.60) 1.43 (1.05,1.96) 0.022* 
S4 rs2383207 0.34 1.48(1.20,1.83) 1.79 (1.32,2.43) 0.0002* 
S5 rs10811656 0.32 1.43 (1.15,1.79) 1.67 (1.22,2.29) 0.0015* 
S6 rs10757278 0.33 0.85  (0.78,0.94) 1.37(1.09,1.72) 0.005* 
S7 rs1333049 0.94 1.21 (1.03,1.43) 1.40(1.05,1.87) 0.013* 
S8 rs10757283 0.27 1.30 (1.05,1.62) 1.47(1.08,2.01) 0.01* 
S9 rs1333047 0.10 0.973(0.878,1.078) 0.92 (0.67,1.25) 0.53 
S10 10757277 0.51 1.063(0.875,1.293) 1.10 (0.81,1.49) 0.54 
S11 10757279 0.32 1.026(0.841,1.252) 1.04 (0.76,1.41) 0.82 
S12 rs3135506 0.09 1.26(1.01,1.57) 1.4 (1.02,1.91) 0.03* 
S13 rs1558861 0.26 1.266(1.014,1.584) 1.44 (1.05,1.98) 0.02* 
S14 rs662799 0.40 0.91(0.84,0.99) 0.60 (0.43,0.84) 0.03* 
S15 rs10750097 0.19 1.50(1.22,1.84) 1.8(1.37,2.51) 0.0001* 
S16 rs599839 0.06 1.19(1.04,1.37) 1.46(1.09,1.94) 0.009* 
S17 rs646776 0.51 0.829(0.740,0.929) 1.62(1.21,2.17) 0.001* 
S18 rs3846663 0.09 0.810(0.720,0.911) 1.72 (1.27-2.32) 0.0003* 
S19 rs2271293 0.31 1.027(0.831,1.269) 1.039(0.764,1.413) 0.8 
HWE = Hardy Weinberg equilibrium test (in control only), OR = odd ratio (representing increase 
risk of MI per risk allele, RR = relative risk, †= Fisher's P value 
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Table 4.7 Genotype frequencies of all variants associated with MI 
  
SNP SNP_ID Genotype 
No.(frequency)  Pearson's 
P 
Fisher's 
P  case control 
S1 rs4977574 AA 87 (0.458) 109(0.568) 0.09 0.09 
  
 
AG 82 (0.432) 67(0.349) 
 
  
  
 
GG 21 (0.111) 16(0.083) 
 
  
S2 rs2891168 AA 60 (0.319) 85(0.467) 0.014 0.014* 
  
 
AG 102 (0.543) 78(0.429) 
 
  
  
 
GG 26 (0.138) 19(0.104) 
 
  
S3 rs2383206 AA 80 (0.417) 106(0.552) 0.0288 0.0289* 
  
 
AG 95 (0.495) 72(0.375) 
 
  
  
 
GG 17 (0.089) 14(0.073) 
 
  
S4 rs2383207 AA 80 (0.391) 107(0.557) 0.001 0.001* 
  
 
AG 84 (0.438) 69(0.359) 
 
  
  
 
GG 33 (0.172) 16(0.083) 
 
  
S5 rs10811656 CC 82 (0.43) 111(0.58) 0.006 0.006* 
  
 
CT 85 (0.443) 65(0.34) 
 
  
  
 
TT 25 (0.13) 14(0.07) 
 
  
S6 rs10757278 AA 81 (0.42) 113(0.59) 0.004 0.004* 
  
 
AG 94 (0.49) 65(0.34) 
 
  
  
 
GG 17 (0.089) 14(0.03) 
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Table 4.7 continue  
 
SNP SNP_ID Genotype 
             No frequency 
  Cases                  Control 
Pearson's 
P 
Fisher's 
P  
S7 rs1333049 CC 44 (0.232) 34(0.177) 0.0664 0.0663 
  
 
CG 89 (0.468) 79(0.411) 
 
  
  
 
GG 57 (0.300) 79(0.411) 
 
  
S8 rs107572783 CC 83 (0.449) 105(0.547) 0.05 0.05* 
  
 
CT 73 (0.395) 70(0.365) 
 
  
  
 
TT 29( 0.157) 17(0.089) 
 
  
S9 rs1333047 AA 82 (0.471) 93(0.484) 0.7 0.71 
  
 
AT 64 (0.368) 74(0.385) 
 
  
  
TT 28 (0.161) 25(0.130) 
  
S10 rs10757277 AA 32 (0.176) 24(0.132) 0.44 0.455 
  
 
AG 70 (0.385) 78(0.429) 
 
  
  
 
GG 80 (0.440) 80(0.44) 
 
  
S11 rs10757279 AA 20 (0.108) 24(0.132) 0.4 0.4 
  
 
AG 90 (0.484) 76(0.418) 
 
  
  
 
GG 76 (0.409) 82(0.451) 
 
  
S12 rs3135506 CC 18 (0.094) 18(0.094) 0.014 0.015* 
  
 
CG 92 (0.479) 65(0.339) 
 
  
  
 
GG 82 (0.427) 109(0.568) 
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Table 4.7 continue 
 
SNP SNP_ID Genotype 
              No frequency 
  Cases                  Control 
Pearson's 
P 
Fisher's 
P  
S13 rs1558861 CC 31 (0.168) 16(0.083) 0.04 0.04* 
  
 
CT 63 (0.341) 68(0.354) 
 
  
  
 
TT 91 (0.49) 108(0.56) 
 
  
S14 rs662799 AA 96 (0.50) 120(0.62) 0.041 0.041* 
  
 
AG 84 (0.43) 61(0.31) 
 
  
  
 
GG 12 (0.06) 11(0.05) 
 
  
S15 rs10750097 AA 37 (0.193) 18(0.094) 0.0006 0.0006* 
  
 
AG 84 (0.438) 69(0.36) 
 
  
  
 
GG 71 (0.37) 105(0.54) 
 
  
S16 rs599839 AA 71 (0.37) 49(0.259) 0.04 0.04* 
  
 
AG 76 (0.396) 81(0.429) 
 
  
  
 
GG 45 (0.23) 59(0.312) 
 
  
S17 rs646776 AA 68 (0.354) 88(0.458) 0.004 0.004* 
  
 
AG 77 (0.401) 81(0.422) 
 
  
  
 
GG 47 (0.245) 23(0.120) 
 
  
S18 rs3846663 CC 75 (0.399) 98(0.510) 0.075 0.075 
  
 
CT 86 (0.457) 75(0.391) 
 
  
  
 
TT 27 (0.144) 19(0.099) 
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Table 4.7 continue  
 
SNP SNP_ID Genotype       No frequency 
Pearson's 
P 
Fisher's 
P  case control 
S19 
  
rs2271293 
AA 27 (0.144) 21(0.109) 0.42 0.42 
AG 64 (0.342) 76(0.396) 
 
  
GG 96 (0.513) 95(0.495) 
 
  
MI= myocardial infarction, SNP= Single nucleotide polymorphism 
 
4.9 Genetic association of APOA5 variants with triglycerides and 
demographic variables 
 Most replicated SNPs rs662799 and rs3135506 of APOA5 were analyzed for 
association with plasma triglycerides and demographic variables Table 4.8. The 
triglyceride raising alleles G of rs662799 and allele C of rs3135506 were significantly 
associated with increased risk of MI. Mean plasma triglycerides level for variant 
rs662799 of homozygous GG (266 mg/dl) was higher in MI patients as compared to 
homozygous AA (189 mg/dl) patients. In MI subjects, the unadjusted geometric mean (β) 
of plasma triglyceride for SNP rs662799 was (1.183, 1.186 and 1.243) in subjects with 
AA, AG and GG genotypes, respectively. Consistent with these results, MI patients 
carrying the CC genotype for variant rs3135506 had higher triglyceride level (β = 1.22, 
95% CI, 0.96-1.56) than CG (β = 1.18, 95% CI, 0.93-1.51) or GG (β = 1.18, 95% CI, 
0.92-1.56) genotypes. Both variants (rs662799, rs3135506) of APOA5 showed significant 
association with plasma triglyceride levels (P=0.03, P=0.05 respectively) among MI 
patients (Table 4.8).  
 The regression analysis of APOA5 for other demographic variables such as age, 
sex, BMI, smoking, hypertension and diabetes was also performed. The analysis showed 
diabetes as a significant risk factor for the onset of MI (P = 0.04 and 0.02 respectively) in 
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comparison between genotypes of both variants (rs662799, rs3135506) (Table 4.9). The 
cases with genotype AA (51%) of rs662799 (APOA5) having diabetes are at high risk of 
MI. Genotype GG (44.9%) of rs3135506 was playing role in onset of  MI in comparison 
to CG (40.8%) and CC (14.3%) genotypes among patients also having diabetes. While 
other independent risk factors did not revealed any association with APOA5 genotypes 
and triglyceride levels and were similar to the main cohort. As shown in Table 4.9. 
 
 
Table 4.8 APOA5 (rs662799 and rs3135506) genotypes in relation to plasma level of 
triglycerides 
 
                  rs662799                      rs3135506 
Parameters AA AG GG CC CG GG 
% (cases/control) 50.0/62.5 43.8/31.8 6.3/5.7 18/9.3 65/33.7 109/56.5 
Cases (mean ± SE) 
mg/dl 
189±  3.3 192±  3.3 266 ± 7.9 244.3 ± 3.8 189 ± 3.2 191±3.7 
Control (mean ± sd) 
mg/dl 
126±2.3 122±2.8 123±4.8 125±4.9 121±2.5 127±2.6 
β  coefficient 1.183 1.186 1.243 1.22 1.18 1.18 
95% CI 0.92-1.51 0.92-1.51 0.97-1.58 0.96-1.56 0.927-1.51 0.92-
1.51 
P† 0.21 0.2 0.03 0.05 0.21 0.2 
P† was tested by multi- logistic linear regression of cases; β =  beta, CI = confidence interval, bold letters = 
representing significant values.
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Table 4.9 Comparison of demographic features between two alleles of rs662799 and 
rs3135506 for MI  patient 
parameters 
rs662799 AA 
(n=96) 
rs662799 AG 
(n=84) 
rs662799 
GG(n=12) P value 
Age (year) 56.8±1.07 53.7±1.2 57±2.8 0.07 
BMI (kg/m2) 29.4±2.3 26.8±0.4 28.5±1.8 0.58 
Smoking (%) 49.5 44.3 6.3 0.91 
Life style (%) 49.8 43.5 6.7 0.74 
Family history (%) 49.1 44.8 6.7 0.71 
Hypertension (%) 43..5 48.1 8.3 0.08 
Diabetes (%) 51 38.8 10.2 0.04* 
 
rs3135506 CC 
(n=18) 
rs3135506 CG 
(n=92) 
rs3135506GG 
(n=82) P value 
Age (year) 59.8±2.2 53.8±1.1 56.7±1.1 0.06 
BMI (kg/m2) 27.8±1.5 26.8±0.5 29.8±2.6 0.48 
Smoking (%) 9.4 48.8 41.8 0.7 
Life style (%) 10.84 47.5 41.7 0.16 
Family history (%) 10.6 49.1 40.3 0.05 
Hypertension (%) 10.2 50.9 38.9 0.48 
Diabetes (%) 14.3 40.8 44.9 0.02* 
All continuous variables are expressed in means ± standard error (SE) and categorical variables are 
expressed in percentage, bold letter= higher values, *=P <0.05 
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4.10 Haplotypes associated with MI in the Pakistani (Punjab) population 
 Haplotype analysis was done for the 4 SNPs of 9p21 locus and 4 genetic variants 
of APOA5 locus which were significantly associated with MI. It provided further support 
for the association of 9p21 locus and lipid metabolism related variants with MI.  
4.10.1 Linkage disequilibrium (LD) and haplotype analysis of 9p21.3 locus 
 LD block map of associated 8 SNPs in 9p21.3 locus (CDKN2A/B gene) was 
shown in Figure 4.9a. (Annexures VI). In this Figure each diamond representing LD 
coefficient (D′) values, while red color of diamonds depicted strong association with 
disease. The D′  values of S1, S2, S7 and S8 indicated these SNPs were not in strong LD. 
Individual block map was also constructed in Figure 4.9b and 4.8c respectively 
representing MI patients with D' 99% (0.99) and correlation coefficient (r2 = 0.94) 
respectively. The haplotype analysis for highly significant genetic variant S3, S4, S5 and 
S6 (chromosome 9p21.3) were shown in Table 4.10. Individual haplotypes of related 
SNPs (S3, S4, S5, and S6) with haplotype G-A-T-G frequency of 33% was significantly 
higher (P = 0.001) in MI group as compared to control 23%. In constrat A-G-C-A and G-
G-C-A haplotypes were significantly lower in MI patients (60%, 3% respectively) verses 
control (70%, 4% respectively) (Table 4.10). 
Table 4.10 Haplotype analysis of SNPs: S3, S4, S5 and S6 
Haplotype Cases (frequency %) Control (frequency %) Pearson's p 
A- A- C- A 15.0(3.9) 8.00 (21) 0.144 
A- A- T- G  0.00 (0.00) 6.23 (16) 0.01* 
A- G- C- A 231.9 (60) 265.8 (70) 0.006* 
G- A- T- G  126.9(33) 86.8 (23) 0.001* 
G- G- C- A 1.00 (3) 13.23 (4) 0.0015* 
A- A- T- A 8.02 (1.) 0.00(0.00) 0.0046* 
Total cases=384, total control=380. Bold value representing risk haplotype 
 Global chi2 is 36.746540 while df=5 (frequency < 0.01 in both control & case has been dropped.) 
Fisher’s P value is 3.77e-015; Pearson’s P value is 6.97e-030 
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Pair-wise Linkage Disequilibrium (LD) analysis 
 
 
 
Figure 4.9 (a): LD block map of associated 8 SNPs in 9p21.3 locus. The pair-wise correlation 
between SNPs was shown as D' value in each diamond. Strong LD is evident 
with red colour (S3, S4, S5 and S6). The SNPs numbers are indicated at the top 
of block 
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Pair-wise Linkage Disequilibrium (LD) analysis 
 
 
 
Figure 4.9 (b): Linkage disequilibrium (LD) block map for highly correlated 4 SNPs in 9p21.3 
locus. It was measured as D' shown in each diamond. Strong LD is evident 
between all four SNPs (S3, S4, S5 and S6) 
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Pair-wise Linkage Disequilibrium (LD) analysis 
 
 
 
Figure 4.9 (c): LD block map for 4 SNPs in 9p21.3 locus, each diamond representing coefficient 
correlation (r2) value. Dark red colour is representing strong association between 
SNPs. 
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4.10.2 LD and haplotype association analysis of APOA5 
 Other LD and haplotype analysis was done for the 4 SNPs (S12, S13, S14 and 
S15) residing in APOA5 gene. It provided further support for the association of APOA5 
locus with MI. The haplotype results were shown in Table 4.11. The values of D′ and r2 
(Figure 4.10a and 4.10b) represented that rs1558861 (S13), rs662799 (S14) and 
rs10750097 (S15) were in strong LD (Annexures VI). The results for individual 
haplotypes of related SNPs (S12, S13, S14 and S15) confirmed that the frequency of C-
T-G-A and G-C-A-G haplotypes were significantly higher (P < 0.05) in MI group as 
compared to control. In contrast G-T-A-G and C-C-G-A haplotypes were significantly 
lower (P < 0.05) in patients verses controls (Table 4.11). 
 
 
Table 4.11  Haplotype analysis of SNP, rs3135506, rs1558861,rs662799, rs10750097 
Haplotype Cases (freq %) 
Control (freq 
%) 
Pearson P Odd ratio[95%Cl] 
G-T-A-G 157.64(0.426) 261.88(0.682) 0.0001 0.357 [0.265~0.481] 
C-C-G-A 36.38(0.098) 80.95(0.211) 0.0001 0.416 [0.273~0.634] 
C-T-G-A 63.42(0.171) 2.05(0.005) 0.0001 39.334 [9.714~159.269] 
G-C-A-A 15.10(0.041) 2.03(0.005) 0.000939 8.150 [1.870~35.521] 
G-C-A-G 56.14(0.152) 9.09(0.024) 0.0001 7.534 [3.679~15.430] 
Total control=384.0, total case=370.0; freq = frequency; bold values depicted risk 
haplotypes; Global chi2 156.941238 while df=8 (frequency f < 0.01 in both case and 
control has been dropped); Fisher's P value is 3.77e-015; Pearson’s P value is 6.97 e-030 
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Pair-wise Linkage Disequilibrium (LD) analysis 
 
 
 
 
 
Figure 4.10(a): LD block map of 4 SNPs of APOA5. The pair-wise correlation between SNPs 
was measured as D' value in each diamond. White color is representing no 
association and red color showing strong association between SNPs. The SNPs 
numbers are indicated at the top of block map 
 
 
 
 
 
98 
 
 
 
 
Pair-wise Linkage disequilibrium (LD) analysis 
 
 
 
 
 
Figure 4.10 (b): LD block map of 4 SNPs of APOA5, each diamond representing r2 values. Key 
as for figure 4.9 a 
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4.11 Family history association  
4.11.1 Variants at 9p21.3 locus confer the risk of MI with positive family history 
 To determine the association between SNPs and positive family history of MI, 
patients with first degree relative who had suffered from MI (n = 121) and MI patients 
without family history (n = 71) were selected. Genotype distribution and allelic 
frequencies of significant SNPs were analyzed and compared with control group (n = 
192). There were significant associations (P < 0.05) of 7 SNPs (S1, S2, S3, S5, S6, S7, 
and S8) with positive family history of MI as compared to control. The association of MI 
was not significant (P > 0.05) for the subgroup of MI without family history (Table 4.12). 
These results suggested the strong association of 9p21.3 locus with positive family 
history of MI. 
 
Table 4.12 Association analysis of all SNPs with positive and negative family 
history of MI 
  
Negative  FH (n = 71) 
  
         Positive FH (n =121) 
  
SNPs P           OR 95% Cl    P                          OR 95% Cl 
rs4977574 0.19 1.31(0.86,2.01) 0.042* 1.43(1.01,2.04) 
rs2891168 0.2 1.25(0.83,1.88) 0.004* 1.63(1.16,2.28) 
rs2383206 0.15 1.36(0.89,2.06) 0.027* 1.48(1.04,2.10) 
rs2383207 0.002 1.87(1.25,2.81) 0.0014 1.74(1.23,2.46) 
rs10811656 0.06 1.47(0.96,2.25) 0.001* 1.79(1.26,2.54) 
rs10757278 0.08 1.45(0.95,2.21) 0.006* 1.63(1.14,2.32) 
rs1333049 0.49 1.14(0.77-1.69) 0.005* 1.58(1.14-2.19) 
rs10757283 0.45 1.17(0.76,1.80) 0.003* 1.67(1.18,2.37) 
P value all compared with192 normal controls, * = P < 0.05, FH = Family history, OR = Odd ratio, CI = 
Confidence interval, MI = myocardial infarction 
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CHAPTER 5 
DISCUSSION 
5.1 Environmental effect on MI 
 MI is multifactorial disease, caused by one or more genes in association and 
interaction with environmental factors (Van der Net et al., 2009). Risk factors associated 
with coronary heart disease in Pakistani population have been relatively less studied 
(Yusuf et al., 2001). The knowledge of these factors in different regions of Punjab, 
Pakistan is of great importance in order to develop national health strategies for their 
control. In demographic section of the current study, it had been found that cardiac 
disease and the risk factors: hypertension, diabetes and obesity were increasing in 
Pakistan. Current data depicted that male MI patients of rural and urban areas of Punjab 
were more susceptible at all age classes particularly at 41-60 years (P < 0.015) as 
compared to females. This is correlated with previous findings that middle aged (41- 60 
years) men have 2 to 5 times higher risk of MI than women (Willcox et al., 2006; Reis et 
al., 2013) and women of young age are protected from risk of coronary heart disease 
(Toyofuku et al., 1996). Estrogen is thought to be a major contributor for premenopausal 
women’s tendency to have normal blood pressure, higher levels of HDL-C, lower 
triglyceride levels and lower risk of MI than men (Wenger et al., 1985; Reslan and 
Khalil., 2012). 
Current results indicated 56% patients with ST Segment Elevation Myocardial 
Infarction (STEMI) as compared to 44% Non ST Segment Elevation Myocardial 
Infarction (NSTEMI) which appeared as major public health problem in Pakistan. Badran 
et al. (2009) previously studied 253 cardiac patients in Egypt, out of which 48% patients 
had more incidence of STEMI as compared to 22% NSTEMI patients The author also 
reported that STEMI was major issue worldwide as compared to NSTEMI. In current 
study prevalence of STEMI was higher than Egyptian population. 
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Smoking was reported as major risk factor for the early onset of myocardial 
infarction accounting 80% increased risk of cardiovascular disease for smokers while 
30% for passive smokers (Yusuf et al., 2001). Smoking deteriorates the HDL-C, raises 
the blood pressure and releases free radicals which cause injuries to heart muscles. 
Among non smokers, who inhaled smoke with passive exposure also greatly increase risk 
of coronary heart disease (Jousilahti et al., 1998). Furthermore, the follow up study 
conducted in Bangladeshi population demonstrated that smoking cessation resulted in 
65% reduced risk of heart diseases (Wu et al., 2013). In current study, the prevalence of 
smoking was more in MI patients 60.9% as compared to 39% non smokers. Furthermore, 
32% smokers were found in rural areas as compared to 28% in urban areas. The study 
reported in rural and urban areas of West Bengal (Eastern part of India) also indicated 
62.3% prevalence of smoking among urban cardiac patients and 16.6% smoking in rural 
cardiac patients which appeared as higher than Pakistani urban MI patients (Misra, 2000). 
The positive association between tobacco smoking and cardiac disease among both men 
and women was clearly demonstrated in both USA (U.S. Department of Health and 
Human Services, 2004) and Shanghai China (Yuan et al., 1996). The study conducted on 
Bangladeshi population indicated that tobacco smoking results in increase premature 
deaths due cancer and cardiac diseases among both men and women (Wu et al., 2013). In 
addition a study reported in Thailand indicated a 2-3 times elevated death rate in smokers 
of all age group in comparison with non-smokers of related ages (Pratipanawatr et al., 
2013). 
Sedentary life style is also an important risk factor for MI (Jayalakshmi et al., 
2011). In present study 70% of MI patients have sedentary life style where it was more 
41% in urban areas as compared to 29% in rural areas. Previously 26% prevalence of 
sedentary life style was reported among coronary heart disease patients in Peshawar, 
Pakistan (Faisal et al., 2011), indicating 44% higher prevalence of sedentary life style 
with MI patients in north Punjab Pakistan. Disturbance in metabolic pathways of 
important compounds (glucose imbalance, lipid metabolism) and heart functions were 
associated with physical inactivity in Australian and Canadian population (Healy et al., 
2007; Katzmarzyk et al., 2009). In an animal modeling study using mice, it was 
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demonstrated that the physical exercise can improve functioning of left ventricle with 
reducing the risk of MI (de Waard and Duncker, 2009). 
 Hypertension is one of the important risk factor responsible for atherosclerotic 
events (Mc Gee, 2005). In present investigation, hypertension emerged as powerful risk 
factor among 37% MI Patients. However, 19.4% urban patients of MI have complaint of 
hypertension as compared to 17% in rural patients. Dietary habits of spicy food (high 
concentration of salt) and high prevalence of obesity with sedentary life style could 
participate in stimulating hypertension which in turn is greatly associated with MI 
(McGee, 2005). Many independent studies have reported higher prevalence of 
hypertension in Pakistan than other South Asian countries (Dodani et al., 2004; Iqbal et 
al., 2004; Javed et al., 2006). The high prevalence of hypertension may be due to poor 
economic conditions and lack of proper health care system in Pakistan.  
Rees et al. (2011) demonstrated diabetes as major public health issue in Pakistan 
and is an important cause of cardiovascular disease (Fuuler et al., 2001; Jafar et al., 
2004). The onset of diabetes in Asian population was reported at young age which varied 
according to culture, ethnicity and urbanization (Chen et al., 2009). In current study the 
distribution of type 2 diabetes was 19.4% in MI patients while it was more prevalent 13% 
among urban patients as compared to 7% in rural patients. The prevalence of diabetes has 
been reported to be significantly higher in urban population as compared to rural 
population of South India which is comparable with Pakistani population (Mohan and  
pradeepa, 2009). The difference in the prevalence of diabetes can be due to change in life 
style or environmental conditions in urban and rural areas of both countries 
(Ramachandran et al., 2008). Moreover, the higher prevalence of diabetes has been 
reported in cardiovascular patients in United State (Rosamond et al., 2008). 
Hyperlipidemia (serum cholesterol level ˃ 200mg/dl) is an important risk factor 
for the development of cardiac diseases (Yusuf et al., 2004). High lipid level can cause 
blockage of coronary arteries and increase the risk of heart attack. The distribution of 
hyperlipidemia was 26% among MI patients in Punjab Pakistan where susceptibility was 
more 19.4% in rural MI patients as compared to 7 % in urban patients. In India 22% of 
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rural population was with hypercholesterolemia (Gupta et al., 2003) which is slightly 
higher to Pakistani (Punjab) population. The higher and comparable cases of 
hyperlipidemia in Pakistani and Indian population can be attributed to the similar dietary 
habits and life style in both areas. Moreover it had been reported that over 7.3 million 
people in Pakistan have elevated cholesterol levels (Yusuf et al., 2004). The data 
obtained from Framingham heart study worldwide has demonstrated that morbidity and 
mortality due to coronary heart disease increases as blood cholesterol level rises 
(O'Donnell and Elosua, 2008). 
 The current study indicated a positive association of higher BMI and development 
of MI. However, positive family history of MI patients got heart disease even at lower 
BMI ≤ 25. In addition Ismail et al. (2004) reported that onset of heart disease at lower 
BMI (≤ 25) was due to consanguineous marriages in Pakistan. Nevertheless, significant 
(P < 0.005) high prevalence of overweight was found in urban areas (31.83%) as 
compared to rural areas (11.64%) of Pakistan. Gupta et al. (2007) reported that higher 
BMI was significantly (P < 0.05) associated with cardiovascular risk factors; 
hypertension, diabetes mellitus and lipid abnormalities resulting in the onset of 
cardiovascular disease. High prevalence of overweight among urban patients was may be 
due to less physical activity and unhealthy dietary practices which includes high 
consumption of saturated fats, refined carbohydrates as well as low consumption of fruits 
and vegetables.  
Difference of disease treatment cost was insignificant (P ˃ 0.05) among all 
economic classes studied presently. Mean estimated annual cost per patient was recorded 
as 9524.53 PKRs (96.96 US$). The calculated cost for cardiac disease treatment varies 
among different countries e.g., from US$ 9512 (Belgium) to 18293 US$ (Austria) per 
year (Tarride et al., 2009). The low and middle income people were facing the 
socioeconomic burden to get their treatment costs. Moreover, the mean calculated cost 
per patient for heart surgery was 600 thousand (6108.19 US$) in Pakistan. One third 
of Pakistani people are living in poverty and cannot afford the increasing treatment 
burden of such costly disease (Iqbal et al., 2004). Hence, due to limited resources 
the heart surgery cost sometimes leads to change in financial capacity of the patients 
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which is making them hypertensive. Suhrcke et al. (2006) had reported cost greatly 
influences complication of coronary heart disease due to financial burden. In USA 
treatment cost was reported to be 32,975 US$/year/patient (Tarride et al., 2009). 
5.2 Genetic association of MI 
Overall Current study was the first to identify three novel SNPs rs10757278, 
rs10811656 and rs10757283 on chromosome 9p21.3 using 11 genetic markers, against 
MI in central Punjabi population of Pakistan. These SNPs were found in two genes 
(CDKN2A/B) on chromosome 9p21.3 are involved in transcription of two proteins (p16 / 
p15) which are inhibitors of cell cycle and were found to be involved in formation of 
atherosclerotic plaque (Wei et al., 2013). The association we observed in Pakistani 
population could not be replicated in other South Asian populations however, the 
comparable mutations were already documented in many ethnicities such as Icelandic, 
Caucasians, South Korean, Chinese and German populations (Helgadottir et al., 2007; 
Kathiresan et al., 2008; Shen et al., 2008; Zeng et al., 2013; Samani et al., 2007).   
The rs4977574 from gene CDKN2A/B having minor allele G frequency greater in 
patients than control was found significantly associated (P = 0.037) with MI. It appeared 
that the allele G of same SNP was responsible for atherosclerosis risk development in 
Pakistani population.  Our findings are in consistent with previous large scale studies on 
Caucasian, Lebanon and Hispanic populations (Kathiresan et al., 2009; Saade et al., 
2011; Qi et al., 2013) where risk allele G was significantly associated with increased risk 
of coronary heart disease. In addition a neighboring SNP rs2891168 located at the 
distance of 45 base pair downstream with risk allele G was significantly associated (P < 
0.05) with the onset of MI. This is comparable with the two independent studies in 
Ontario, London and Italian populations which confirm the G as a risk allele for the 
development of coronary heart disease (P < 0.05) (Lanktree et al., 2008; Shen et al., 
2008). 
The SNPs rs2383206, rs2383207 and rs1333049 from gene CDKN2A/B were in 
strong association with MI in single site and genotype analysis (P < 0.05). Ahmad et al. 
(2013) strengthen the association of rs1333049 with risk allele C against MI in North 
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(Islamabad, Murree) of Pakistan. The same findings were found in Canadian and 
Icelandic studies  for association with cardiovascular disease (Helgadottir et al., 2007; 
Mc Pherson et al., 2007). Moreover, the SNPs rs10757278 (risk allele G), rs10811656 
(risk allele T) located only 5 base pair (bp) apart from each other were significantly 
related (P < 0.05) with disease.  In consistent to current findings Zeng et al. (2013) has 
reported genetic marker rs10757278 at 9p21.3 locus (CDKN2A/B) was significantly 
associated with coronary heart disease in Chinese Han Population. Many independent 
studies of different races (Korea, Caucasian, and Iceland) have also depicted strong 
association of SNPs with cardiac disease (McPherson et al., 2007; Helgadottir et al., 
2007; Shen et al., 2008). 
The ANRIL promoter region have obligatory site for Zn-finger proteins that are 
important for transcription of CDKN2A/B (Rodriguez et al., 2010). The genetic marker 
rs10757283 coupled with ANRIL gene at base position of 22134172 in chromosome 
9p21.3 locus with risk allele T significantly contributed with the onset of MI at allele and 
genotype levels (P < 0.05). Current results contradict prior report for SNP rs10757283 
association with coronary heart disease in Chinese population where risk allele C was 
associated with disease (Cheng et al., 2011).  Moreover present findings support prior 
association of rs10757283 risk allele T with coronary heart disease in European 
population (Silander et al., 2009). The difference of risk allele between populations may 
be due to diversity in defining phenotypes. 
 In present study none of the 3 SNPs rs1333047, rs10757277 and rs10757279 
(chromosome 9p21.3 locus) depicted significant association with MI. These findings are 
in contrast with prior report by Zeng et al. (2013) that these 3 SNPs (rs1333047, 
rs10757277 and rs10757279) were significantly associated with coronary heart disease in 
Chinese Han population. The negative results of these SNPs are useful to consider since 
the difference in study population and ethnicity due to environment, life style or 
mutations specific to populations. 
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5.2.2 Genetics of lipid metabolism related SNPs 
 The Apolipoprotein gene APOA5 has been related previously with onset of 
various diseases such as thickness of common carotid artery intimae media and greatly 
increased in levels of triglycerides which leads to atherosclerosis, furthermore involved in 
atherosclerotic plaque composition (Garelnabi et al., 2013).   
APOA5 gene was previously replicated from Chinese population in association 
with various cardiovascular diseases (Cheng et al., 2011). Currently the gene was 
replicated in Pakistani population and identified with four genetic markers (rs3135506, 
rs1558861, rs662799 and rs10750097) significantly associated (P < 0.05) with MI. The 
patients with minor allele C for SNPs rs3135506 and rs1558861 were at higher risk of MI 
onset. Minor allele (C) of SNP rs3135506 was also found to be involved in changing the 
signal activity of APOA5 through amino acid replacement thus lowering the amount of 
functioning protein in British population (Talmud et al., 2004). The frequency of minor 
allele G for genetic markers rs662799 and rs10750097 from APOA5 was higher in cases 
28% and 41% in comparison to control 20% and 27% respectively. Minor allele G 
frequency (28%) of APOA5 SNP rs662799 was comparable with Chinese population 
(29.9%) (Liu et al., 2009). However, the same allele was found in low frequency (0.8%) 
in European white population (Pennacchio et al., 2001). Present results are in contrast to 
previous findings where allele C was minor with 32% frequency among cardiovascular 
patients for SNP rs662799 in population of Morocco (Ouatou et al., 2014). These 
variations among gene frequency were may be due to ethnic diversity between 
populations. 
 Furthermore, the two genetic markers (rs662799 and rs3135506) from APOA5 
were found to be significantly associated with plasma triglyceride levels. Polymorphisms 
in database SNP rs662799 confined in the promoter region of APOA5 plays role in 
APOA5 mRNA translation, which in turn results in less APOA5 levels and then it leads to 
higher plasma triglyceride levels (Palmen et al., 2008). The mean plasma triglyceride 
levels for variant rs662799 homozygous for G allele was 266 mg/dl higher than 
homozygous for allele A (189 mg/dl) in MI patients. In contrast to current findings mean 
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plasma triglyceride level for SNP rs662799 with genotype GG 112 mg/dl and genotype 
AA 90 mg/dl was reported in Australian population (Laurila et al., 2010). The higher 
levels of triglycerides in Pakistani population than Australian population may be due to 
the heterogeneity and life style including eating habits etc. Moreover genetic variant 
rs3135506 was significantly associated with mean plasma triglyceride level of 244 mg/dl 
for CC genotype in association with GG and CG with plasma triglyceride concentration 
of 191mg/dl and 189 mg/dl in MI patients. In contrast to present findings mean plasma 
triglyceride levels for SNP rs3135506 with genotype homozygous for C was 145 mg/dl, 
90 mg/dl among homozygous G and 80 mg/dl for heterozygous was also lower in 
Australian population (Laurila et al., 2010). Furthermore, Ken-Dror et al. (2010) reported 
minor allele C of the same SNP was associated with 34% increased level of triglyceride 
concentration in immigrants to Israel.  The results are also consistent with the previous 
findings that APOA5 one of the most important genetic determinants affecting 
triglyceride levels which lead to atherosclerosis in German population (Cullen, 2000; Li 
et al., 2007). 
 There was no significant association among genotypes of the same SNPs 
(rs662799 and rs3135506) with demographic characteristics except diabetes. The diabetes 
was found significant (P = 0.04) risk factor among MI patients for homozygous AA in 
comparison with AG and GG genotypes of SNP rs662799. Diabetes was reported as 
strong predictor of cardiovascular disease in European population and in white 
population of USA (Qi et al., 2013; Adams et al., 2014). 
 Three genes (PSRC1 /CELSR2 /SORT) located on chromosome 1p13. SNP were 
located in the intergenic region of these three genes (Kooner et al., 2008) and taking part 
in regulating plasma low LDL-C levels, mutations in these genes can cause imbalance in 
LDL-C levels (Linsel-Nitschke et al., 2010). Genetic variants within this region, 
rs599839 and rs646776 risk allele G were significantly associated with MI (P < 0.05). 
Both of these SNPs were increasing the susceptibility of MI in Pakistani population. 
Previously it was reported same allele G associated with reduce risk of myocardial 
infarction in New Zealand (Muendlein et al., 2009). The contradictory results depicted 
that two SNPs (rs599839, rs646776) were reported protective against the development of 
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MI in New Zealand natives However, were at high risk in Pakistani population. 
Moreover, previously reported both variants (rs599839, rs646776) has been associated 
with increase levels of LDL-C which ultimately was associated with coronary 
atherosclerotic lesion in Europeans, South Asian and Hispanics (Kathiresan et al., 2009; 
Linsel-Nitschke et al., 2010; Saleheen et al., 2010; Qi et al., 2011).  
In present study another genetic variant rs3846663 was identified in HMGCR 
gene, 3 hydroxy-3-methylglutaryl-coenzyme A-reductase (HMG-CoA reductase) playing 
key role in in cholesterol biosynthesis and elevating the risk of MI. The genotypes TT 
and CT were more susceptible in cases than control. The homozygous genotype TT of the 
SNP rs3846663 was also reported the risk allele associated with higher LDL-C level and 
high risk of CHD in Caucasians (Kathiresan et al., 2009). 
 The SNP rs2271293 (NUTF2 gene) located on locus 16q22 controls HDL-C 
levels however, did not show any association with MI (P=0.8). Similar findings were 
reported by Voight et al. (2012) who found no association of variant rs2271293 (P = 
0.10) in European population. 
5.3 Linkage disequilibrium analysis 
Linkage disequilibrium analysis was carried out between 4 variant (rs2383206, 
rs2383207, rs10811656 and rs10757278) of CDKN2A/B gene located in 9p21.3 locus and 
4 genetic markers (rs3135506, rs1558861, rs662799 and rs10750097) of APOA5 gene 
found on chromosome 11. Haplotypes were constructed, for those highly significant 
variants located in strong linkage disequilibrium. 
Variants rs2383206, rs2383207, rs10811656 and rs10757278 (chromosome 9p21) 
were in strong LD. Current study identified G-A-T-G haplotype with frequency 33% in 
MI group was higher as compared to 23% in control. These findings support that certain 
haplotypes and LD patterns at 9p21.3 being useful in describing genotype disease 
association in MI. Haplotype and LD analysis of SNPs (rs3135506, rs1558861, rs662799 
and rs10750097) residing in APOA5 gene provided further support for the association of 
APOA5 locus with MI. Present study identified C-T-G-A and G-C-A-G haplotypes as 
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risk haplotypes significantly (P = 0.0001) associated with MI. Laurila et al. (2010) 
identified APOA5 risk haplotypes (C-A-C-G and G-G-C-G) were different from current 
study associated with lipid profile. This association of APOA5 polymorphism (at 
genotyping, haplotype and linkage disequilibrium level) with MI, for the first time in our 
population, has been well established. 
 When the case group for 9p21.3 locus was divided into two subgroups; the 
significant association was identified only in sub group with positive family history of 
MI. This study is in line with findings of Shen et al. (2008) that strong family history was 
a strong predictor for onset of cardiac disease in Italian population. 
5.4 Conclusion 
 Current data demonstrated people living in urban areas have higher level of MI 
risk factors (Physical inactivity, hypertension and diabetes) and therefore should be 
treated as “high risk group” for prevention and treatment. Moreover, this study 
demonstrated effective risk factors control is still poor in Punjab, Pakistan. Therefore 
public health programs including life style interventions along with different 
pharmacological therapy should be implanted in order to reduce the risk of coronary 
heart disease in Pakistan. Preventive efforts are needed to start early in life and should 
continue throughout the life course. Second phase of study (genetic analysis) is the first 
that has endeavored to explore the correlation between polymorphism of 9p21.3 locus 
and APOA5 gene for the onset of MI in Pakistani population of province Punjab. 
 Present data indicates that the SNPs, rs10757278 risk allele G, the rs10811656 
risk allele T and the rs10757283 risk allele T are associated with high risk of MI. 
Moreover, current findings support the role of APOA5 in raising triglyceride level. The 
present confirms that Polymorphism in variants of APOA5, CELSR2 and HMGCR genes 
may lead to the progression of MI. However, further studies are needed for genetic 
mapping to elaborate the genetic role of lipid metabolism related SNPs in Pakistan. 
Knowledge of genetic factors contributing to onset of MI may be helpful for diagnostic 
methods, treatment and preventive measures for this disease. There is a need for replicate 
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studies at large scale to determine the role of genetic variants in pathology of MI which 
can be helpful in early prediction as well as control and prevention of this disease. 
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ANNEXURE I 
Patient No.: ____________________________ Date: ________________________________ 
 
Information Performa for Cardiac Patients (myocardial infarction) 
Personal Information: 
Patients name _________________                       Father’s name ___________________ 
Age: _________________                                     Gender :M/F   
Marital status: _________________                      Cousin marriage/out of family               
Phone number: _________________                     Residence number_______________ 
Age at the time of diagnosis:_______                     Duration of MI:____________ 
Postal 
address__________________________________________________________________
________________________________________________________________________
__________________________ 
Weight:__________height:___________       Body mass index:______________ 
Number of individuals in house:__________    caste:______________________ 
Educational level: 
*Illitrate  *up to primary *Secondary to intermediate *Graduate and above 
Employment Status: 
Job(govt/private)        *retired                   *jobless                    *Businessman 
Monthly house hold income in rupees: 
Up to 5000                            *10,000-20,000                                 *<30,000 
Socioeconomic status: 
Low                                    *Middle                                             *High 
Family history 
Parents                                 *sister/brother                                  *grandparents or any other 
Life style: 
Physical activity            exercise/walk 
Have smoked:                yes/no 
Present smoking status:        *daily        *ocassionaly             *not smoking at present 
Smoking ( packs/month):          __________ 
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Other complication with heart attack: 
Diabetes  
hypertension 
angina pectoris 
Coronary artery surgery (angioplasty, stent, or coronary bypass 
Hyperlipidemia 
coronary artery obstruction 
 Nutrition 
In a typical day, indicate how many servings you eat or drink of the following:          
Breads, cereals, rice :____________                 Fruits:   ____________  
Vegetables  _________                                      Dairy products (milk, yogurt)______    
Cups of tea __________                                     Water (8 oz.)   ___________ 
Fast food ___________                                       Red Meat:______________     
Chicken  _____________                                   fish_______________ 
Which of the following do you typically eat and/or use in cooking?   Oil/ghee 
How many times in week do you eat out? _____ Breakfast     Lunch      Dinner     
Are you currently taking any medication: yes/no 
Name of regular used 
medicines___________________________________________________ 
Heart attack 
history:_________________________________________________________________
________________________________________________________________________
___________ 
 
 
 
 
 
 
 
155 
 
ANNEXURE II 
DNA Extraction 
Frozen blood samples were thawed at room temperature. TE buffer of (500-700 
µl) was mixed with 500 µl blood. mixed by inverting tubes ups and down several times 
and left at room temperature or 10-15 min. Centrifugation was done at 25oC with 13500 
rpm for 5-10 min. Supernatant was discarded leaving the WBCs pellet at the bottom of 
1.5 ml eppendorf, broke the pellet by gentle tapping or vortexing, added 1 ml TE buffer, 
performed mixing and repeated steps 2 and3 until the WBCs pellet became light pink or 
clear. The broken clear pellet was dissolved into 375 µl of 3M sodium acetate, 25 µl of 
10% SDS and 5-10 µl of proteinase K (10 µg/µl) and incubated at 37oC overnight in a 
shaking water bath. One volume of chilled chloroform: isoamyl alcohol (24:1) was added 
into 3 volumes of digested pellet, mixed by gently inverting eppendorfs ups and down 
until a milky emulsion was formed and centrifuged at 25oC with 13500 rpm for 5-10 min.  
Three layers can be visualized after centrifugation. The upper layer contains DNA, the 
lower layer chloroform: isoamyl alcohol and the middle whitish layer proteins. The DNA 
layer was carefully transferred into a new labeled eppendorf avoiding contamination from 
other layers, mixed with equal volume of chilled absolute ethanol by gently inverting 
eppendorfs ups and down until DNA threads became visible, left at room temperature for 
10 min and centrifuged at 25oC with 13500 rpm for 5-10 min. (8) Supernatant was 
discarded and the DNA pellet was washed with 500-1000 µl chilled 70% ethanol by 
centrifuging at 25oC with 13500 rpm for 5-10 min. (9) Ethanol was discarded and the 
DNA pellet was dried by air keeping eppendorfs open inside the laminar air flow at room 
temperature for 15-30 min. (10) The dried DNA pellet was dissolved into 50-100 µl low 
TE buffer, incubated in a shaking water bath at 70oC for 30 min, cooled at room 
temperature and spinned by brief centrifugation. (11) DNA was stored in duplicate at -
20oC or -80oC after assessing its quality and quantity by spectrophotometery or gel 
electrophoresis. Then we measured the DNA concentration by nanodrop method and 
visually after electrophoresis in 1% agarose gel and was stored at -20 °C.  
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ANNEXURE III 
1st PCR (Gradient PCR), Reaction mixture 
PCR Components              volume of each well               volume of half plate 
 Forward primer (FP)                                              6.25 µl (Each primer) 
 Reverse primer (RP)                                              6.25 µl (Each primer) 
 Master Mix 4    µl                    50x                         200 µl 
 H2O 14.5µl __________                                         705 µl 
 Taq pol 0.3 µl                                                          15 µl 
 DNA 0.6 µl                                                              30 µl 
             20 µl                                                                       1000µl 
 
  A 96-well PCR plate was used for optimization process in which at a time eight 
set of primers were tested (Figure 3.1 & 3.2). For one PCR plate, reaction mixture was 
prepared in two eppendorf tubes.  Then loaded the reaction mixture to 8 eppendorfs (230 
µl to each eppendorf tube and add 6.25 µl of each primer forward & reverse). In PCR 
plates 117 µl of above mixture was added in column 1 & 7 then separate mixture to 2-6 
and 8-12 wells (same primer sample in same row), the final volume of each well was 
20µl. Used film to seal the plate and short spin for 7 seconds. Gradient PCR program as 
described above was used (Figure 1). 
1st PCR material 
Forward primer           0.5 µl                                              25 µl 
Reverse primer            0.5 µl                                               25 µl 
Master mix                      4µl                       50x                200 µl 
H2O                            14.   1µl                      ______          705 µl 
Taq pol                            0.3 µl                                                          15 µl 
DNA                                   0.6 µl                                                 30 µl 
                                        20 µl                                            1000µl 
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                     54◦C                   56◦C             58◦C                60◦C                 62◦C              64◦C 
 1 2 3 4 5 6 7 8 9 10 11 12 
A(1pp) 1 2 3 4 5 6 7 8 9 10 11 12 
B(2pp) 13 14 15 16 17 18 19 20 21 22 23 24 
C(3pp) 25 26 27 28 29 30 31 32 33 34 35 36 
D(4pp) 37 38 39 40 41 42 43 44 45 46 47 48 
E(5pp) 49 50 51 52 53 54 55 56 57 58 59 60 
F(6pp) 61 62 63 64 65 66 67 68 69 70 71 72 
G(7pp) 73 74 75 76 77 78 79 80 81 82 83 84 
H(8pp) 85 86 87 88 89 90 91 92 93 94 95 96 
Figure 1: Optimization of primers (gradient PCR at six different temperatures) 
pp: pair of primers 
 
2nd PCR Material 
Forward primer        0.3 µl                                                   15 µl 
Reverse primer         0.3 µl                                                    15 µl 
Master Mix                   4 µl                           50x                  200 µl 
H2O                          14.5µl                 _________________ 725 µl 
Taq pol                    0.3 µl                                                      15 µl 
DNA                        0.6 µl                                                        30 µl 
                                    20 µl                                                    1000µl 
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ANNEXURE IV 
Agarose Gel Electrophoresis 
It was used to determined the of PCR products (presence or absence) and quantify 
the size (length of the DNA molecule) of the product. 
Materials needed: 
Agarose 
TAE Buffer 
6X Sample Loading Buffer 
DNA ladder standard 
Electrophoresis chamber 
Power supply 
Gel casting tray and combs 
Recipes: TAE Buffer 
4.84 g Tris Base 
1.14 ml Glacial Acetic Acid 
2 ml 0.5M EDTA (pH 8.0) 
maked the total volume up to 1L with water 
Added Tris base to ~900 ml H2O. Added acetic acid and EDTA to solution and 
mixed. Poured mixture into 1 L graduated cylinder and added H2O to a total volume of 1 
L. For convenience a concentrated stock of TAE buffer of 10X was made and was diluted 
with water to 1X concentration before use. 
6X Sample Loading Buffer 
1 ml sterilize H2O 
1 ml Glycerol 
Enough bromophenol blue to make the buffer deep blue (~ 0.05mg) 
Preparing the Agarose gel 
Measure 1 g of Agarose powder and add it to a 500 ml flask. Add 100 ml TAE Buffer to 
the flask. Heated the agarose in a microwave until the solution became clear. The solution 
was cooled to about 50-55°C and added 5 l of Ethidium Bromide (Sigma E7637) in 100 
ml solution, swirling the flask occasionally to cool evenly. Place the combs in the gel 
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casting tray. Poured the melted agarose solution into the casting tray and cooled it until it 
is solid (it should appear milky white). Carefully pull out the combs. Placed the gel in the 
electrophoresis chamber. Added enough TAE Buffer so that it’s about 2-3 mm of buffer 
over the gel. 
Loading the gel 
Added 3 l of Sample Loading Buffer to 2l of PCR product on a thin film and 
mix it. The order of the samples loading was recorded. Carefully pipette 5 l of each 
sample Loading Buffer mixture into separate wells in the gel. Pipette 2 l of the DNA 
ladder (1kb, Fermentas) into at least one well of on the gel. 
Running the gel 
Placed the lid on the gel box, connecting the electrodes. Connected the electrode 
wires to the power supply, making sure the positive (red) and negative (black) were 
correctly connected. Turned on the power supply, about 100 volts. Checked to make sure 
the current is running through the buffer by looking for bubbles forming on each 
electrode. Checked that the current running in the correct direction by observing the 
movement ofthe blue loading dye. The power run until the blue dye approaches the end 
of the gel. Turn off the power. Disconnected the wires from the power supply. Remove 
the lid of the electrophoresis chamber. Carefully removed the tray and gel and DNA 
bands were observed (BioRad, Gel doc system) 
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ANNEXURE V 
The best method was selected for OLE assay. Following data representing OLE 
test for one SNP i.e. rs10757278. Following values were calculated by using following 
formula= +ve value- (-ve value) × 100             Here +ve is that sample for which  
                          -ve value                                     +ve florescent dye was used 
 
Table:  OLE test results for rs10757278 by using OLE one base extension method. 
     
 
     one base F    one base R 
 
A* G* U* C* 
               AA 243 192 312 185 
                GG 237 221 164 308 
                AG 291 225 305 259 
             water 115 131 87 139 
     
 
128 61 225 46 
 
122 90 77 169 
 
176 94 218 120 
homozygous 2.531646 15.10417 90.2439 66.48649 
heterozygous 22.78481 17.1875 85.97561 40 
Here F = forward primer; R = reverse primer, AA,GG,AG = three genotypes of template DNA;  highlighted 
value showing best method for OLE assay is one base reverse 
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ANNEXURE V continue 
Table  : Results of OLE assay from OLE plate using method one base reverse for rs10757278 
OLE 
readings (i) 
dye 
1 2 3 4 5 6 7 8 9 10 11 12 
dUTP* 304 204 291 306 289 286 291 115 299 166 268 270 
dCTP* 140 93 176 139 175 147 137 181 170 190 172 98 
dUTP* 180 219 314 164 253 303 286 105 305 151 283 270 
dCTP* 193 119 169 99 167 153 113 98 168 177 181 171 
dUTP* 290 192 135 298 284 254 284 295 274 293 292 282 
dCTP* 174 171 185 99 147 175 162 143 175 161 189 108 
dUTP* 287 218 297 242 214 292 294 285 291 280 289 289 
dCTP* 187 196 143 178 180 118 151 158 131 174 180 156 
dUTP* 259 116 183 286 305 272 293 298 292 289 269 206 
dCTP* 179 179 191 148 148 145 154 175 144 167 138 170 
dUTP* 291 192 309 308 302 282 297 301 279 229 118 118 
dCTP* 107 90 109 158 159 92 110 174 125 172 94 168 
dUTP* 251 124 110 215 292 314 251 288 285 283 274 267 
dCTP* 179 114 177 107 111 195 108 152 139 134 95 143 
dUTP* 313 316 276 282 197 280 281 284 280 280 180 75 
dCTP* 120 174 103 173 183 114 166 140 159 129 136 76 
     
   (a)              
Calculated 
values (ii) 
      dye 1 2 3 4 5 6 7 8 9 10 11 12 
dUTP* 3.07  1.73  2.90  3.10  2.87  2.83  2.90  0.54  3.01  1.23  2.58  2.61  
dCTP* 0.84  0.22  1.31  0.83  1.30  0.93  0.80  1.38  1.23  1.49  1.26  0.29  
dUTP* 1.41  1.93  3.21  1.20  2.39  3.06  2.84  0.41  3.08  1.02  2.78  2.62  
dCTP* 1.53  0.57  1.23  0.30  1.20  1.01  0.49  0.28  1.21  1.33  1.37  1.24  
dUTP* 2.89  1.57  0.80  2.99  2.80  2.40  2.80  2.96  2.68  2.93  2.91  2.78  
dCTP* 1.29  1.24  1.44  0.30  0.93  1.30  1.13  0.88  1.30  1.11  1.48  0.42  
dUTP* 2.84  1.93  2.97  2.25  1.87  2.91  2.94  2.81  2.89  2.75  2.87  2.87  
dCTP* 1.46  1.57  0.88  1.34  1.36  0.55  0.98  1.08  0.72  1.29  1.36  1.04  
dUTP* 2.47  0.56  1.45  2.83  3.08  2.64  2.93  2.99  2.91  2.88  2.60  1.76  
dCTP* 1.36  1.35  1.51  0.95  0.94  0.90  1.02  1.30  0.90  1.19  0.81  1.24  
dUTP* 2.90  1.57  3.14  3.12  3.05  2.78  2.98  3.04  2.74  2.06  0.58  0.58  
dCTP* 0.40  0.18  0.43  1.08  1.09  0.22  0.44  1.29  0.64  1.26  0.24  1.20  
dUTP* 2.36  0.65  0.47  1.87  2.92  3.20  2.36  2.85  2.82  2.80  2.67  2.58  
dCTP* 1.35  0.50  1.33  0.40  0.47  1.57  0.42  1.00  0.83  0.76  0.25  0.88  
dUTP* 3.19  3.23  2.70  2.78  1.64  2.75  2.77  2.81  2.75  2.75  1.41  0.00  
dCTP* 0.58  1.28  0.36  1.28  1.41  0.49  1.18  0.84  1.09  0.70  0.79  0.00  
                                                                                   (b) 
Controls 
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       (Continue) 
            OLE  
results  
(iii) 1 2 3 4 5 6 7 8 9 10 11 12 
 
GA AA GA GA GA GA GA GG GA GG GA AA 
 
GG AA GA AA GA GA AA 00  GA GG GA GA 
 
GA GG GG AA GA GA GA GA GA GA GA AA 
 
GA GG GA GA GG AA GA GA GA GA GA GA 
 
GA GG GG GA GA GA GA GA GA GA GA GG 
 
AA AA AA GA GA AA AA GA AA GA 00  GG 
 
GA 00  GG  00 AA GA AA GA GA GA AA GA 
 
AA GA AA GA GG AA GA GA GA GA GG control  
                                                                                    (C) 
 
 
 
 
  
 
 
  
 
 
 
   
Table: (a) Showing FP values from multilable counter of 192 samples for rs10757278, here 
last two wells for control (use water). Table (4.7 b) representing calculated values. 
Highlighted blocks represents value for basic genotypes according to baseline (≤ 0.5 is AA; 
≥ 1 is TT) and Table (4.7 C) representing related resulted genotypes after reading values. 
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ANNEXURE VI 
 
Table 1: Pair-wise LD-based associations with MI. D' values of 8 SNPs of 9p21.3 locus 
 
D' S1 S2 S3 S4 S5 S6 s7 S8 
S1 _ 0.36 0.494 0.52 0.517 0.54 0.058 0.5 
S2 _ _ 0.03 0.026 0.036 0.045 0.035 0.016 
S3 _ _ _ 0.897 0.91 0.961 0.006 0.426 
S4 _ _ _   -   1 0.993 0.024 0.471 
S5 _ _ _   -     -   0.993 0.018 0.497 
S6 _ _ _   -     -     -   0.026 0.53 
S7 _ _ _ _ _ _ _ 0.009 
Bold values are D' > 0.05 
 
Table 2:  Pair-wise haplotype-based associations with MI.  r2 values of 8 
associated SNPs 
 r2 S1 S2 S3 S4 S5 S6 S7 S8 
S1 _ 0.094 0.238 0.231 0.262 0.284 0.001 0.229 
S2 _ _ 0.001 0.001 0.001 0.001 0.001 0 
S3 _ _ _ 0.705 0.824 0.877 0 0.169 
S4 _ _ _ _ 0.869 0.821 0 0.207 
S5 _ _ _ _ _ 0.944 0 0.232 
S6 _ _ _ _ _ _ 0 0.249 
S7 _ _ _ _ _ _ _ 0 
Bold values are r2 > 0.05 
 
Table 3 : Pairwise haplotype  D' and r2 values for APOA5 SNPs 
D' S1 S2 S3 S4 
S1 _ 0.50 0.976 0.922 
S2 _ _ 0.526 0.563 
S3 _ _ _ 1.000 
S4 _ _ _ _ 
r2 S1 S2 S3 S4 
S1 _ 0.25 0.743 0.694 
S2 _ _ 0.213 0.259 
S3 _ _ _ 0.636 
S4 _ _ _ _ 
  Bold values:  D' > 0.5;  r2' > 0.5 
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ANNEXURE V11 
Preparation of solutions 
 
1L 1M Tris-HCl Weigh 121.1g tris base (2-Amino-2-hydroxymethyl-propane-1,3-diol), 
dissolve into 700 ml distilled H2O, adjust pH to 7.4-8.0, raise final volume to 1L, 
autoclave and “if possible” filter the solution and store at room temperature.  
 
1L 3M sodium acetate Weigh 246.1 × 3g sodium acetate, dissolve into distilled H2O, 
adjust pH to 5.2, raise final volume to 1L, autoclave and “if possible” filter the solution 
and store at room temperature.  
 
1L 10M NaOH Weigh 40 × 10g sodium hydroxide (NaOH), dissolve into 700 ml distilled 
H2O, raise final volume to 1L and store at room temperature.   
 
1L 1M HCl Measure 86.2 ml of 11.6M HCl, dilute into 913.8 ml distilled H2O and store 
at room temperature. Precaution Add acid into distilled H2O not distilled H2O into acid.    
 
1L 0.5M EDTA Weigh 372.2/2g ethylene-diamine-tetraacetic acid (EDTA), dissolve into 
700 ml distilled H2O, adjust pH to 8.0 by using NaOH pellets or 10M NaOH solution, 
raise final volume to 1L, autoclave and “if possible” filter the solution and store at room 
temperature. Note The dissolution of EDTA is pH-sensitive. EDTA will start dissolving 
on stirrer only when pH is increased towards 8.0 by the pellet-wise or drop-wise addition 
of NaOH into the starting mixture. Once EDTA solution becomes clear, stop adding 
NaOH. If excessive NaOH is added during EDTA dissolution, pH may become greater 
than 8.0, which will then be adjusted to 8.0 by using 1M HCl.  
 
1L TE buffer (10 mM Tris-HCl, 2 mM EDTA, pH 8.0) Dilute 10 ml of 1M Tris-HCl 
solution and 4 ml of 0.5M EDTA solution into 500 ml distilled H2O, raise final volume to 
1L and store at room temperature. 
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50 ml 10% SDS Dissolve 5g sodium dodecyl sulphate (SDS) into 45 ml distilled H2O, 
heat up to 68oC for  dissolution, adjust pH to 7.2 by using 1M HCl and “if possible” filter 
the solution and store at room temperature. Note Don’t use fume hood while preparing 
SDS solution.  
10 ml 10 µg/µl proteinase K Dissolve 100 mg proteinase K into 10 ml distilled H2O, 
make aliquots of 100 µl and store at -20oC. 
 
500 ml chloroform: isoamyl alcohol (24:1) Mix 480 ml chloroform into 20 ml isoamyl 
alcohol and store at 4oC.  
 
500 ml 70% ethanol Mix 350 ml absolute ethanol into 150 ml distilled H2O and store at 
4oC.    
 
100 ml low TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) Dilute 1 ml of 1M Tris-
HCl solution and 200 µl of 0.5M EDTA solution into 50 ml distilled H2O; raise final 
volume to 100 ml and store at room temperature. 
 
10 ml 10 µg/µl ethidium bromide (EtBR) Dissolve 100 mg EtBR into 10 ml distilled H2O 
or low TE buffer, make aliquots of 1 ml, cover tubes with aluminum foil and store at 
room temperature. Note EtBR is a strong mutagen and protection from exposure is 
needed. 
 
50 ml 6× loading dye Dissolve 0.125g bromophenol blue (0.25%), 0.125g xylene cyanol 
FF (0.25%) and 15 ml of 100% glycerol (30%) or 20g sucrose (40%) or 7.5g Ficoll type 
400 (15%) into distilled H2O for making final volume up to 50 ml and store at 4
oC or -
20oC. 
 
50 ml 6× restriction stop/loading dye Dissolve 0.05g bromophenol blue (0.1%), 1g Ficoll 
type 400 (2%) and 1.86g EDTA (100 mM) into distilled H2O for making final volume up 
to 50 ml and store at 4oC or -20oC.       
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1L 10× TBE buffer Dissolve 108g tris-borate, 55g boric acid and 40 ml of 0.5M EDTA 
solution into 700 ml distilled H2O, raise final volume to 100 ml and store at room 
temperature.  
 
1L 1× TBE buffer Dilute 100 ml of 10× TBE buffer into 900 ml distilled H2O and store 
at room temperature.  
1 ml 25 mM dNTPs Mix 250 µl of each of 100 mM dNTPs (dATP, dGTP, dCTP and 
dTTP) for making a 25 mM dNTPs solution containing all four dNTPs in equimolar 
concentration and store at -20oC. 
 
1 ml 2.5 mM dNTPs Dilute 100 µl of 25 mM dNTPs solution into 900 µl distilled H2O 
and store at -20oC. 
 
100 ρmoles oligoes or primers Multiply nmoles of lyophilized oligoes or primers with 10. 
The answer will provide a µl volume of low TE buffer for dissolution of these lyophilized 
oligoes or primers for making 100 ρmoles or 100 µM solution and store at -20oC. 
Example If a lyophilized oligo or primer contains 40.2 nmoles, dissolve into 420 µl low 
TE buffer, concentration of the solution will be 0.1 nmoles, 100 ρmoles or 100 µM. 
 
1 ml 10 ρmoles oligoes or primers Dilute 100 µl of 100 ρmoles oligoes or primers’ 
solution into 900 µl distilled H2O and store at -20
oC. 
 
25 mM MgCl2 and PCR buffer PCR buffers and 25 mM, 50 mM or 100 mM MgCl2 are 
provided alongwith purchased Taq DNA polymerase (10 U/µl) and are used as such. 
Therefore, recipes for solution preparation and dilutions of these PCR reagents are not 
given. 
